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Change in Circulating Klotho in Response to Weight Loss, with and without Exercise, 
in Adults with Overweight or Obesity 
Katherine A. Collins, PhD 
University of Pittsburgh, 2019
The increased risk in aging-related comorbidities associated with obesity is a significant public 
health concern. Weight loss via lifestyle intervention has been shown to improve negative health 
outcomes; however, the mechanistic pathway by which this occurs is unknown. One biomarker 
of importance is Klotho, with higher levels being associated with slower aging processes. 
Evidence has shown Klotho to be lower in obese adults compared to normal-weight adults. 
Exercise may independently increase levels of Klotho; however, whether the effects on Klotho 
are enhanced when exercise is included within the context of a weight loss intervention is not 
understood. Purpose: The primary aim was to examine changes in Klotho concentration in 
response to a behavioral weight loss intervention, by intervention condition, and weight loss 
response. Methods: Three hundred and eighty-three overweight and obese adults (age: 45.0+7.9 
years; BMI: 32.4+3.8 kg/m2) were randomized to DIET, DIET+PA150, and DIET+PA250. One 
hundred fifty-two of 383 participants provided blood samples at all time points, and were 
classified as “responder” or “non-responder” for this study. The intervention contained a 
prescribed calorie restricted diet (1200-1800 kcal/day) and increased physical activity (0-, 150-, 
250 min/week). Intervention groups attended weekly in-person group sessions for months 1-6, 
with combined in-person and telephonic sessions for months 7-12. Results: Participants had 
significant reductions in weight, BMI, and body composition, and increased cardiorespiratory 
fitness across the 12-month intervention. Klotho concentration also significantly, increased 
across the 12-month behavioral weight loss intervention (p=0.010); however, there was no 
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difference by intervention group or weight loss response. Although non-significant, participants 
who performed physical activity had greater changes in Klotho concentration across the 12-
month intervention. Further, Klotho concentration was found to be inversely associated with lean 
body mass (p=0.021). Conclusion: This study provides evidence within the context of a weight 
loss intervention, that Klotho concentration significantly, but modestly, increases with weight 
loss. However, despite sustained weight loss, this increase in Klotho was not sustained 
throughout the intervention. Results do not support weight loss drive Klotho response. However, 
non-significant results support physical activity to influence Klotho, within the context of obesity 
and weight loss. Further investigation to examine how weight loss and physical activity may 
alter biomarkers of aging in adults with obesity is warranted. 
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1.0 Introduction 
1.1 Background 
Overweight and obesity are associated with major health risks and increase in premature 
death.1,2 Overweight is defined as having a body mass index (BMI) > 25 kg/m2 to <30 kg/m2, 
and obesity is defined as having a body mass index of >30 kg/m2.1,3,4 The current prevalence of 
obesity is estimated to be 35.5% among adult men and 35.8% among adult women,3,5 with 
obesity having an increase in prevalence compared to levels of a few decades ago among adults 
in the United States.3,4 The increased prevalence of obesity is of significant public health concern 
due to its association with many chronic diseases such as cardiovascular disease, diabetes, 
certain cancers, sleep apnea, osteoarthritis, musculoskeletal problems, and others.5-10 The health-
related consequences of obesity are enhanced at higher levels of obesity.5,6   
The health-related concerns of obesity may be a result of excess body weight promoting 
accelerated aging by affecting the maturation of adipose tissue, influencing inflammation and 
glucose homeostasis, promoting insulin resistance, oxidative stress, DNA damage, telomere 
dysfunction, increased vasomotor tone, increased sympathetic drive, and more.1,3 The accelerated 
aging that occurs with obesity may serve as the pathway for increased risk in diabetes and 
cardiovascular disease. Of the many biomarkers that have been investigated, very few have been 
identified to play a role in the longevity pathway. Vascular endothelial growth factor (VEGF), 
brain-derived neurotrophic factor (BDNF), and insulin-like growth factor (IGF) – 1 have been 
identified as potential biomarkers that lie along the molecular pathway of aging.11 VEGF-A has 
been identified for its role in angiogenesis, BDNF plays a part in neurogenesis, and IGF-1 
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promotes growth and maintenance of muscle.  While these biomarkers may provide a better 
understanding to human longevity, their influence on the molecular pathway of longevity 
appears to be associated with downstream effects rather than being markers of early detection in 
accelerated aging.  
One biomarker that may be provide insight to accelerated aging is Klotho, as it has been 
found to be associated with longevity, as well as, cardiovascular and neuroprotective effects with 
higher levels of Klotho being associated with a slower aging process and fewer negative-health  
outcomes.12,13 Thus, Klotho may be an important biomarker to understand the pathways of 
accelerated aging that may be present with overweight and obesity (Figure 1); however, there is 
limited data available on this relationship, with even less data available on how Klotho responds 
to weight loss using lifestyle intervention.   
 
Figure 1. Potential Pathway to Explain the Effect Weight has on Aging 
 
Klotho was first discovered by Kuro-o et al. in 1997, who found an insertion mutation on 
the 5’ flanking region of α-Klotho in mice, that was associated with several symptoms of 
premature aging including soft tissue calcification, arteriosclerosis, skin atrophy, gonadal 
dysplasia, infertility, hypoglycemia, server hyperphosphatemia, osteoporosis, emphysema, and 
an overall shorter life span.12,13 Human Klotho is primarily expressed in the kidney, but is also 
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detectable in the placenta, prostate, and small intestines.13  The majority of circulating Klotho 
results from proteolytic cleavage of the intracellular domain of the full-length protein by 
secretases. 14 The current understanding of Klotho is based on its ability to exert both fibroblast 
growth factor-23 (FGF23) dependent and FGF-23 independent, pleiotropic actions with soluble 
Klotho acting as both a paracrine and endocrine factor.12,14,15  
Secreted Klotho acts as a humoral factor that is linked to nitric oxide production in the 
endothelium, regulation of calcium channel activity, suppression of oxidative stress, 
transforming growth factor-β1 signaling, and insulin/IGF-1 signaling.16 Klotho has been 
identified as having two homologs,  β-Klotho and α-Klotho. α-Klotho is the primary homolog 
that has been studied and is associated with anti-aging factors, whereas β-Klotho is less 
understood but thought to be associated with inflammation and fat oxidation.11   
1.2 Clinical Significance 
There is a limited evidence that has examined the association between body weight, or 
measures of adiposity, and Klotho. Of the published data that are available, lower Klotho levels 
have been observed in adults with obesity compared to those who are of normal body weight.17  
Animal studies also link Klotho to obesity and suggest that Klotho may play a role in energy 
metabolism, white adipose tissue accumulation, reductions in the consequences of consuming a 
high fat diet, and insulin resistance.18,19  However, the effects of weight loss in adults with 
obesity on Klotho has not been examined, and therefore it is unclear if intentional weight loss in 
adults with obesity would result in favorable improvements in Klotho and thereby potentially 
provide a mechanistic pathway by which health improvements are obtained in response to weight 
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loss.  Thus, key contributions of this proposed study examined the relationship between Klotho 
and body weight, body composition/lean mass, and cardiorespiratory fitness in adults who are 
overweight or obese prior to initiating a weight loss program.  Moreover, this study examined 
whether intentional weight loss using lifestyle intervention resulted in favorable changes in 
Klotho (Figure 2).  
Figure 2. Potential Pathway to Explain the Effect of Diet, Exercise, Weight and Body Fat on Klotho Level 
 
Another key aspect in the study of Klotho is the influence of exercise, 11 which also 
appears to be an important lifestyle behavior for body weight regulation, prevention of lean 
muscle mass loss, and prevention and treatment of numerous health-related conditions.20 It has 
been suggested that similar anti-aging effects that are linked with exercise and physical activity 
are also linked to Klotho.11  There is evidence to support performing exercise may result in an 
increase in Klotho.  Following a 16-week exercise training program, individuals with a BMI >30 
kg/m2 showed a significant increase in Klotho concentration in response to an acute exercise 
bout.11  Dalise et al. demonstrated that following a 30-minute bout of exercise there was 
significant upregulation of Klotho in mice.21 However, particularly related to obesity, studies 
have not examined whether exercise coupled with dietary restriction to induce weight loss 
enhances the Klotho response compared to dietary restriction alone.  Thus, an additional 
contribution of this proposed study was to examine Klotho response to weight loss induced by 
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dietary restriction compared dietary restriction combined with exercise in adults with overweight 
or obesity.  Moreover, given the design of this study, we were able to examine whether the dose 
of prescribed exercise has any additional influence on change in Klotho within the context of a 
behavioral weight loss intervention.  
This study examined Klotho in stored blood samples from a completed randomized 
clinical trial to determine: 1) the association between Klotho and level of overweight or obesity 
prior to weight loss, and 2) the change in Klotho across a 12-month behavioral weight loss 
program that included diet alone or diet plus exercise in high and low responders to the 
intervention.  The behavioral weight loss intervention included participants randomized to one of 
three interventions: 1) Diet Alone [DIET], 2) Diet + 150 minutes of moderate-to-vigorous 
physical activity [DIET+PA150], 3) Diet + 250 minutes of moderate-to-vigorous physical 
activity [DIET+PA250] (Figure 3).  Using this design, the following specific aims were 
examined.   
 
 
 
 
 
 
 
 
 
 
Figure 3. Conceptual Framework of 3 Different Weight Loss Strategies on Circulating Klotho Levels 
6 
1.3 Specific Aims 
1. To examine the association between circulating Klotho and BMI, parameters of body 
composition (fat, lean mass), and cardiorespiratory fitness in sedentary adults who are 
overweight or obese prior to engaging in a behavioral weight loss intervention. 
2. To compare the effect of three intervention conditions (DIET, DIET+PA150, 
DIET+PA250) on circulating Klotho levels across a 12-month intervention. 
3. To examine whether change in Klotho differs between individuals classified as high 
responders to the behavioral weight loss intervention (>10% of baseline weight) and 
those individuals classified as low responders to the behavioral weight loss intervention 
(<5% of baseline weight).  
1.4 Hypotheses 
1. It is hypothesized that there will be in inverse association between BMI and circulating 
Klotho levels, with individuals at a lower BMI having higher levels of circulating Klotho. 
A similar inverse association will be observed when examining the association between 
body fatness and Klotho, with a lower level of body fatness reflecting a higher level of 
circulating Klotho. However, there will be a positive association between lean body 
mass, cardiorespiratory fitness, and circulating Klotho.  
2. It is hypothesized that there will be a significant difference in circulating Klotho between 
intervention conditions across the 12-month intervention with both the DIET+PA150 and 
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DIET+PA250 resulting in higher levels compared to DIET. Moreover, DIET+PA250 will 
result in higher levels of circulating Klotho compared to DIET+PA150.  
3. There will be a significant difference in circulating Klotho across the intervention 
between individuals classified as high responders and low responders, with circulating 
Klotho being significantly higher in high responders compared to low responders.  
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2.0 Review of the Literature 
2.1 Overweight and Obesity 
2.1.1  Prevalence 
Overweight, defined as a body mass index (BMI) >25kg/m2 to <30kg/m2, and obesity, 
defined as a BMI of >30kg/m2, are prevalent in 33.9% and 35.1% of US adults respectively.3   
According to the National Health and Nutrition Examination survey the prevalence of 
overweight and obesity is 68.8% overall, and 73.9% among men and 63.7% among women.4  
The overall prevalence of obesity is higher among middle-aged adults compared to their younger 
counterparts. Also, there is a higher prevalence among non-Hispanic black and Hispanic adults 
compared to non-Hispanic white and non-Hispanic Asian adults.1   
2.1.2  Consequences of Obesity 
Over the past decade obesity has become a global epidemic, with dramatic increases in 
both adults and children. With this, both men and women who are overweight or obese are at an 
increased risk of developing numerous health conditions.7 These including a number of 
comorbidities such as, metabolic syndrome2,6, cardiovascular disease2,6,8,22, type 2 diabetes2,6,8,22, 
hypertension2,6,8,22, certain cancers6,8,22, and sleep apnea6,9,10. Obesity has been estimated to be 
associated with an excess of 112159 deaths from cardiovascular disease alone.22   
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Along with increased mortality rates, overweight and obesity are associated with 
increased health service use which has led to an economic burden among this population. 
Abdominal adiposity assessed by waist circumference has been linked to increased total 
healthcare expenditures, independent of age, gender, ethnicity, and smoking status. 6 In 1998, it 
was found that the medical cost of obesity was estimated to be roughly $78.5 billion, with almost 
half of the cost funded by Medicare and Medicaid.23 In 2006, Finkelstein et al. found that 
overweight and obese patients were spending $1,429 more, or about 42% higher, on healthcare 
costs compared to their normal weight counterpart. This annual medical burden has increased 
from 6.5% to 9.1% of annual medical spending and could be as high as $147 billion per year 
based off a National Health Expenditure Accounts estimate.23 The increased prevalence of 
overweight and obesity has not only causes physical burden on individuals, but also emotional 
and financial burden.  
2.1.3  Factors Affecting the Etiology of Obesity 
Overweight and obesity are complex multifactorial disease states, with their origins 
stemming from an imbalance between energy intake and energy expenditure. Overweight and 
obesity are affected by both environmental and genetic factors, with the interaction between the 
two leading to increases in body weight and fat accumulation.24   Figure 4 displays four primary 
factors that have been shown to lead to overweight and obesity modeled from Weinsier et al., 
Ravussin et al., and others; genetic predisposition, metabolic, appetite and dietary and physical 
inactivity.25-27  
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Figure 4. Factors Effecting the Etiology of Overweight and Obesity 
Genetic predisposition is thought to be one of the multiple factors that can cause an individual to 
develop obesity. There have been multiple hypotheses developed in order to attempt to 
understand what role genetics exactly plays. The “thrifty genotype” hypothesis developed by 
Neel et al., discusses how throughout evolution, humans had to go through periods of time where 
they would feast and overeat in order to survive and this over time made individuals more 
susceptible to fat accumulation. However, even though at one point in time this was a means to 
survive, in the current obesogenic environment, this adaptation has become a liability.26,28,29 
Speakman et al., developed the “predation release” hypothesis arguing that millions of years ago 
the act of predation was removed from the humans everyday life with the development of 
weapons, fire and social behaviors. This shift in lifestyle led to a modification in the population 
distribution of body fatness due to genetic drift and random mutations. Speakman et al., believes 
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that obesity is due to this random genetic drift, rather than direct selection. Meaning individuals 
still have the ability to remain thin, even if they are living in an obesogenic environment.29,30   
Metabolic factors including energy expenditure and fuel utilization are key contributors 
to becoming overweight or obese. Energy expenditure is comprised of three components, resting 
energy expenditure, thermic effect of food, and activity expenditure.25-27,29  Although each 
components’ contribution to total energy expenditure is variable, typically the smallest 
contribution comes from the thermic effect of food and the largest from resting energy 
expenditure.25,31 Resting energy expenditure is highly dependent on body mass, in particular fat-
free mass, as it is considered more metabolically active compared to fat tissue. When considering 
absolute resting energy expenditure, individuals who are overweight or obese typically have a 
higher resting energy expenditure because of the increased body size, but when this is adjusted 
for lean body mass, resting energy expenditure is comparable among normal, overweight, and 
obese individuals.25 Resting energy expenditure, however, has not been shown to predict weight 
gain, and has only a small impact on an individual’s ability to gain weight. Conversely, total 
energy expenditure has been shown to be inversely correlated with rate of weight gain.  This 
suggests it may be important to increase activity in order to increase total energy expenditure as a 
potential way to prevent the onset of obesity.25-27,29   
Substrate utilization via respiratory quotient has also been found to be associated with 
weight gain. In both the Pima Indians study and The Baltimore Longitudinal Study, it was found 
that a high respiratory quotient, meaning low fat oxidation, is suggested to be a metabolic index 
as a predictor of weight gain.25,26,32 However, there have been findings to contradict these 
studies, therefore more research is needed to understand the fuel utilization mechanism and its 
relation to weight gain.  
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Appetite and dietary factors have also been found to be associated with weight gain. 
Leptin is a gene primarily expressed in adipose tissue, known to regulate body weight. 
Contradictory evidence has been found with leptin concentrations and the impact it has on 
weight gain. Some report low plasma levels of leptin to be predictive of weight gain.25,26,33 
Others have found higher plasma leptin levels to be associated with weight gain.25,33  There have 
been many dietary factors found to be associated with those who have a higher body mass index. 
These include, a dietary intake of higher energy density foods, high ethanol intake, frequent 
intake of sugared beverages, high intake of meat and processed meat, larger portion sizes, 
absence or bad location of supermarkets, and “fast food,” which have all been found to be 
associated with weight gain.24 Lifestyle factors including low physical activity, alcohol use, 
smoking, too much or too little of sleep, and too much television time have also been found to be 
associated with increased weight gain.24,25  
Physical inactivity or sedentary behavior have been found to have an inverse relationship 
to adiposity or weight gain.25 According to the World Health Organization24, every year at least 
1.9 million people die as a result of physical inactivity.  On the contrary, if an individual 
performs 30 minutes of regular physical activity 5 days a week, their risk for many chronic 
diseases is decreased, as well as a decrease risk for all-cause mortality independent of risk 
factors.24 Chronic diseases influenced by physical inactivity include, hypertension, type 2 
diabetes mellitus, musculoskeletal diseases, mental health disorders, ischemic heart disease, and 
certain cancers, among others. 2,6,8,22,24   
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2.2 Weight Loss and Weight Loss Maintenance Intervention Components 
2.2.1  Behavioral Therapy Component  
Behavioral therapy refers to principles and techniques used to change a participant’s 
behavior and habits.34,35 The goal of behavioral treatment is for individuals to adopt changes to 
their lifestyle by reducing caloric intake and increasing energy expenditure. Behavioral 
techniques are typically used in conjunction with other weight loss components including dietary 
and physical activity changes. There are various strategies used to help modify participant 
behavior including self-monitoring, stress management, stimulus control, problem solving, 
contingency management, cognitive restructuring of thoughts, social support, and relapse 
prevention training.34-36 Although the content of behavioral therapy is important, how often it 
occurs has also been shown to play an important role in an individual’s weight loss success. Ross 
et al., found that when an individual is actively trying to lose weight, group meetings should 
occur at a minimum of once a month but would have better success if they occurred bi-weekly or 
weekly, to provide nutrition education, reinforcement, encouragement, and monitoring.34-37   
2.2.2  Dietary Component 
The dietary component of a weight loss intervention is important when an individual is 
initiating weight loss. To produce weight loss, the calories an individual consumes should be 
fewer than the amount they expend, producing an energy deficit. Studies show that individuals 
should reduce their caloric intake to generate a deficit of 500 to 1000 kcal/day to produce a 1 to 2 
lb/week weight loss.34 Low calorie diets are typically recommended for weight loss with an 
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average calorie intake range from 800 kcal/day to 1800 kcal/day. 34,36,38-40 Low calorie diets have 
shown to produce an average of 8% weight loss in individuals who are overweight or obese over 
a 6-month period.34,36,38,39  
2.2.3  Physical Activity Component 
Physical activity is a key component to weight loss interventions and sustaining long 
term weight loss and maintenance. Physical activity increases total energy expenditure, may 
inhibit food intake, and may improve quality of life both physically and mentally in 
individuals34.  The exercise portion of a weight loss intervention can be supervised or 
unsupervised, meaning either the participants have to come into the research center and perform 
their prescribed dose of physical activity, or they perform it on their own outside of the research 
center.36,39,41 Physical activity prescriptions are generally based on the American College of 
Sport Medicine Position Stand42, which states that individuals should perform 150 minutes/week 
of moderate or 75 minutes/week of vigorous aerobic physical activity for substantial health 
benefits and to produce weight loss.  For greater health benefits, long-term weight loss, and 
weight maintenance it is recommended to perform 200-300 minutes/week of moderate to 
vigorous aerobic physical activity.42,43 The strategy in which individuals decide to accumulate 
physical activity minutes does not seem to matter provided that the physical activity period is a 
minimum of 10 minutes to sum to 30 minutes or more or performing one bout of 30 
minutes.34,42,43 However, evidence included the 2018 Physical Activity Guidelines Advisory 
Report highlights the potential benefits of performing activity in bouts of less than 10 minutes in 
duration.20    If studies include resistance training in their prescribed exercise it is recommended 
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to perform muscle-strengthening activities that are moderate to high-intensity and involve all 
major muscle groups on 2 or more days of the week.44  
2.2.4  Combined Therapy 
Studies show that diet only interventions produce weight loss, they have poor long-term 
outcomes and physical activity only interventions produce poor weight loss outcomes.34  To 
produce the best outcome for long-term weight loss success and weight maintenance including 
both a dietary component and physical activity component in an intervention is important. Long-
term follow-up studies have found that patients who are physically active on a regular basis 
achieve enhanced maintenance of weight loss.34,45 The inclusion of behavioral therapy has also 
been shown to be important to improve weight loss success and long-term weight loss. Wing et 
al., reviewed studies that focused primarily on changing eating behavior, changing physical 
activity, and motivational strategies to improve weight loss and found that the most effective 
weight loss program included all three components of diet, physical activity, and behavior 
modification.34,36,46,47 The greatest weight loss success was found when all of these components 
were maintained for at least 6 months.34,36,46,47  
2.2.5  Long-Term Weight Loss Maintenance 
Individuals tend to have success in the short term while still participating in a weight 
reduction program. However, following the program is when individuals relapse and frequently 
regain most if not all their lost weight within 1 to 5 years of the program.34,36 The US Institute of 
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Medicine found that individuals who participate in a weight reduction program typically lose 
10% of their body weight, but within 1 year  two-thirds of the weight is regained.34,37 
The National Weight Control Registry is a self-selected population of adults 18 years or 
older that have loss 13.6 kg and has kept it off at least 1 year.48  Three strategies that individuals 
among this population perform on a regular basis include: consuming a low-calorie diet, 
performing high levels of physical activity, and weighing themselves frequently.49 High levels of 
physical activity have been found to be associated with greater weight loss maintenance success 
compared to individuals in a diet alone weight loss program.50 Registry members report an 
average energy expenditure of 2545 kcal/week in women and 3293 kcal/week in men of physical 
activity.48,49 Although it is accepted that physical activity plays an important role in weight loss 
maintenance, the amount of physical activity that is needed continues to remain uncertain.  
In the 2009 American College of Sports Medicine Position Stand it was recommended 
for long term weight loss maintenance that an individual perform 200-300 min/week of physical 
activity, almost equivalent to the levels of physical activity performed by individuals in the 
registry. 42,43  Jakicic et al., provides data from a randomized control trial that indicates those 
individuals who perform greater amounts of physical activity maintain a greater amount of 
weight loss at 12-month follow-up.42,51,52 The trials also show very little weight regain in 
individuals who performed >200 minutes/week of moderate intensity physical activity. 42,51,52   
Similarly, Jakicic et al., reported that those individuals who achieved a weight loss of >10% of 
initial body weight at 24 months, were currently participating in 275 minutes/week of (~1500 
kcal/week) of physical activity above baseline levels.42,53 Jeffery et al.,54 randomly assigned 
individuals to either 1000 and 2500 kcal/week of physical activity for 18 months, and found the 
reported energy expenditure of kcal/week at 18 months was 1629 + 1483 and 2317 + 1854 for 
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the 1000- and 2500-kcal/week groups, respectively.42 They also found no differences for weight 
loss between groups at 6 months, but there were significant differences at 12-, and 18-months of 
follow-up, with the 2500 kcal/week group indicating significantly greater weight losses.42,54 In 
summary, these studies indicate, along with physical activity recommendations, that greater 
amounts of physical activity result in lower levels of weight regain and improved weight loss 
maintenance.  
2.3 Weight Loss in Relation to Health 
Overweight and obesity places individuals at a greater risk for development of many 
chronic related conditions. Treatment of overweight and obesity through weight loss via lifestyle 
intervention has been shown to decrease mortality rates, as well as, reduce the risk for these 
negative health-related outcomes.55 Health benefits from weight loss using a lifestyle 
intervention approach appear in individuals with as little as 5% weight loss from baseline, with 
greater benefits appearing at >10% weight loss.55,56 It is typically recommended that individuals 
reduce their calorie intake by 500 to 1000 kcal per week, in order to produce a 1 to 2 lb per week 
weight loss, resulting in a 10% weight loss by 6 months. This percentage of weight loss has been 
shown to be clinically meaningful in lowering blood pressure, levels of total cholesterol, LDL 
cholesterol, triglycerides, blood glucose levels, and increase HDL cholesterol levels, among 
other health outcomes.55,57 
 The 2013 American Heart Association/American College of Cardiology/The Obesity 
Society guidelines on the management for overweight and obesity found strong evidence linking 
weight loss to health outcomes. In overweight and obese adults with type 2 diabetes who 
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achieved 5% to 10% weight loss in 1 year of lifestyle intervention, were found to have 
reductions in hemoglobin A1c of 0.6% to 1.0% and a reduced need for diabetic medications.57 In 
adults with overweight or obesity who achieve 5 kg to 8 kg of weight loss via lifestyle 
intervention see reductions in LDL cholesterol by approximately 5 mg/dL and improvement in 
HDL cholesterol by 2 to 3 mg/dL.57 In overweight and obese adults with an elevated 
cardiovascular risk, a weight loss of 5% has been shown to reduce systolic and diastolic blood 
pressure by 3 and 2 mmHg, respectively.57      
2.4 Physical Activity in Relation to Health 
Physical activity is defined as any bodily movement produced by skeletal muscles that 
results in energy expenditure.58 Exercise represents a subset of physical activity that is planned, 
with a goal of improving or maintaining fitness.59 The 2018 Physical Activity Guideline 
Advisory Report states individuals can reach substantial health-related benefits from physical 
activity by doing 150 to 300 minutes of moderate intensity physical activity or 75 to 150 minutes 
of vigorous intensity physical activity. To achieve greater health-related benefits individuals 
should perform > 300 minutes of physical activity per week.20,59   
The 2018 Physical Activity Guideline Advisory Report states there is strong evidence in 
adults to suggest a relationship between physical activity and health benefits including lower risk 
for all-cause mortality and CVD mortality, lower risk for CVD, hypertension, type 2 diabetes, 
adverse blood lipid profile, certain cancers (bladder, breast, colon, endometrium, esophagus, 
kidney, lung, and stomach), improved cognition, reduced risk of dementia, improved quality of 
life, reduced anxiety and risk of depression, improved sleep, slowed or reduced weight gain, 
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weight loss (typically when combined with a reduced calorie diet), prevention of weight regain 
following initial weight loss, improved bone health and physical function, lower risk of falls and 
fall-related injuries.20  
There are several biological outcomes that are associated with the health benefits of 
performing physical activity. Regularly participating in physical activity has been shown to 
improve body composition60-65, enhance lipid lipoprotein profiles60,66-73, improve glucose 
homeostasis and insulin sensitivity60,61,74-77, reduce blood pressure74,78,79, improve autonomic 
tone80,81, reduce systemic inflammation80, decrease blood coagulation60,66, improve coronary 
blood flow60,66, augment cardiac function60,66, and enhance endothelial function82-85.60  
Physical activity has been found to produce a decreased risk for all-cause mortality and 
cardiovascular disease. An increase in energy expenditure by 1000 kcal per week or increase in 
physical fitness of 1 MET has been shown to be associated with a mortality benefit of 20%.60 
Conversely, physically inactive women whom engage in 1 hour or less of physical activity per 
week, are shown to have a 52% increase risk for all-cause mortality, doubling in risk for 
cardiovascular disease related mortality, and a 29% increase in cancer related mortality. Similar 
risks have been found among men.60,79,86,87 Wessel et al., studied 936 women who had undergone 
a coronary angiography for myocardial ischemia, and found that individuals who had higher 
physical fitness scores had significantly less coronary artery disease risk factors, less angiogenic 
coronary artery disease, and lower risk for cardiovascular adverse events.86,88  
Physical activity has also been shown to reduce risks associated with type 2 diabetes. 
Helmrich et al., examined in a large prospective cohort study, that each 500 kcal increase in 
energy expenditure per week was associated with a decreased incidence of type 2 diabetes by 
6%. This finding was prominently found in those whom were at a high risk of developing 
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diabetes (i.e. individuals with a high BMI).60,89 Interventions on physical activity have also 
shown to be effective in management of type 2 diabetes. Wei et al., found that physically 
inactive men with diagnosed type 2 diabetes had a 1.7-fold increased risk of premature death 
compared to their physically active counterparts.60,90  
A study examining physical activity levels among breast, colorectal, and prostate cancer 
survivors found that those who participated in physical activity levels recommended by the 
American Cancer Society, (i.e. 30 minutes of moderate intensity physical activity on at least 5 or 
more days a week) reported significantly greater health-related quality of life compared to 
individuals who just adhered to dietary recommendations.88 Studies in cancer patients of both 
breast and colon have looked as physical activity levels, and those individuals whom self-
reported being physically active were found to have a decreased recurrence of cancer and risk of 
death from cancer.60,91  
Physical activity has also been shown to provide health benefits regardless of BMI in 
adults. The fitness-fatness hypothesis suggests a higher level of cardiorespiratory fitness can 
substantially reduce adverse effects of obesity on morbidity and mortality, potentially making 
obesity not as important of a risk factor as generally believed. It has been found in multiple 
studies and meta-analyses that un-fit individuals have twice the risk of mortality regardless of 
BMI, compared to normal weight-fit individuals.  Overweight and obese-fit individuals have a 
similar mortality risk as normal weight-fit individuals.92-96 Again, suggesting performing 
physical activity and improving cardiorespiratory fitness is important for reducing negative 
health-related outcomes regardless of BMI.  
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2.5 Background on Klotho 
The accelerated aging that occurs with obesity and the mechanism by which this occurs is 
of importance in order to better understand the increased risk for many negative health-related 
outcomes. One biomarker that may provide insight into to accelerated aging is Klotho. It was 
first discovered by Kuro-o et al., in 1997, who found an insertion mutation in the 5’ flanking 
region of α-Klotho in mice that was associated with several symptoms of premature aging, 
including soft tissue calcification, arteriosclerosis, skin atrophy, gonadal dysplasia, infertility, 
hypoglycemia, severe hyperphosphatemia, osteoporosis, emphysema, and an overall shorter life 
span.12,13 Human Klotho is primarily expressed in the kidney, but is also detectable in the 
placenta, prostate, and small intestines.13 Circulating Klotho results from either direct secretion 
by the cell or from cleavage of the intracellular domain of the full-length protein by secretases. 
Both processes lead to ‘soluble’ Klotho, which is found in blood, urine, and cerebrospinal fluid.14 
It was originally thought that Klotho functioned primarily as a coreceptor for FGF23 binding to 
FGF receptor 1, and that their cooperativity function was restricted to the ectodomain of 
membrane Klotho. However, the current understanding is that Klotho exerts both FGF23-
dependent and FGF23-independent, pleiotropic actions, while soluble Klotho acts as both a 
paracrine and endocrine factor.12,14,15  
Klotho is thought to enter into the circulation system through three different potential 
pathways, (1) alternative RNA splicing, (2) proteolytic cleavage, (3) movement of Na+, K+-
ATPase (adenosine triphosphatase). (1) Klotho genes can directly generate the secreted form of 
klotho protein by alternative RNA splicing, liberating klotho into the extracellular space and 
subsequently, the circulation.97,98 (2) The transmembrane form of the klotho protein could also 
be cleaved by members of the ADAM (a disintegrin and metalloproteinases) family, and released 
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into the circulation system (Figure 5).98,99 (3) Klotho is primarily expressed in kidney cells, but 
is not present on the cell surface, rather it is diffusely expressed in the cytoplasm, and overlaps 
on the endoplasmic reticulum and Golgi apparatus. It has been reported that in the endoplasmic 
reticulum and Golgi apparatus, the premature and mature form of klotho can bind to Na+, K+-
ATPase. In this process, the klotho - Na+, K+-ATPase complex are potentially going up to the 
cell surface where klotho can be cleaved and secreted into the extracellular space and eventually 
the circulatory system.98,100 With research leaning towards proteolytic cleavage as the primary 
pathway of secreted Klotho, the major source of secreted klotho still remains yet to be 
confirmed.   
 
Figure 5. Primary Pathway Klotho Enters the Circulation, Proteolytic Cleavage. 
Two Primary Cleavage Sites have been Identified in the Klotho Protein, One between the KL1 and KL2 
Domains (β-cut) Cleaved by ADAM10, and the Second near the Transmembrane Region (α-cut) Cleaved by 
ADAM17. Adapted from Xu et al with Copyright permission.  
 
As a hormone, Klotho targets multiple tissues and organs that result in anti-aging and 
cardiovascular protective properties. It reduces oxidative stress by inhibiting insulin and insulin-
like growth factor-1 signaling pathways. It enhances endothelial nitric oxide production leading 
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to an improvement in endothelium-dependent vasodilation. It is an endogenous inhibitor of 
vascular calcification and it decreases cell-surface abundance of the Ca2+ channel TRPC6. This 
calcium channel is expressed in cardiac, glomerular, and vascular smooth muscle cells, and plays 
a vital role in the regulation of vascular resistance and blood pressure.  The upregulation of 
TRPC6 leads to cardiac hypertrophy and glomerulosclerosis, therefore when Klotho 
downregulates the channel there is a potential protective effect.14,101 Klotho may also influence 
many other pathways including the p53/p21 signal pathway, cAMP signal pathway, PKC signal 
pathway, and Wnt signal.98  
Normal serum Klotho levels have been inconsistently studied, with results varying. 
Pedersen et al., analyzed Klotho on two different immunoassays to establish an assay specific 
reference interval for healthy adults. It was found that serum Klotho levels were significantly 
higher in time-resolved fluroescecne immunoassay (TRF) compared to an ELISA (IBL), with no 
correlation found between the assays. For the TRF immunoassay the reference interval for serum 
Klotho in males was 11-181ng/mL and for females 19-316ng/mL, respectively. In the ELISA 
immunoassay the reference interval was 204-741pg/mL, and no differences were found between 
genders. It was also found that serum Klotho levels were independently associate with estimated 
glomerular filtration rate and body weight with the TRF immunoassay, but with ELISA serum 
Klotho was only found to be associated with age.102  
Klotho and its association to aging and longevity,  has been found to be associated with 
other aging biomarkers including VEGF-A, IGF-1, and BDNF.21  BDNF has been found to be 
involved in the process of neurogenesis, which is defined as the formation of new neurons from 
neural stem cells and progenitor cells which occurs in various brain regions such as the 
subgranular zone of dentate gyrus in the hippocampus and the subventricular zone of lateral 
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ventricles.21,103 VEGF–A has been found to be involved in the process of angiogenesis, which is 
defined as the generation of new capillary blood vessels.21,103 IGF-1 has been linked to the 
promotion of growth and maintenance of muscle.21  While these biomarkers provide insight to 
human longevity, their influence on the molecular pathway of longevity appears to be associated 
with downstream effects rather than markers of early detection in accelerated aging.  
2.6 Associations Between Klotho and Health-Related Outcomes 
Low Klotho concentration has been linked through several studies to negative health-
related outcomes including heart disease, cognition and brain health and musculoskeletal health. 
Klotho has been identified as the “anti-aging hormone,” and so understanding where Klotho falls 
in these negative health-related outcome pathways is important in understanding how Klotho 
functions.  
The Invecchiare in Chianti (Aging in Chianti study) “InCHIANTI” study, is an 
epidemiological research study primarily examining older adults and biomarkers, risk factors, 
and physiological subsystems of adults in order to provide better insight into precision medicine. 
This study has identified a relationship between low plasma Klotho levels and health outcomes 
including cognitive decline, poor grip strength, and cardiovascular disease.104,105  
Shardell et al.,105 examined 833 participants aged 55 years and older without dementia 
that were enrolled in the InCHIANTI study. Cognition was measured using the Mini-Mental 
State Examination (MMSE) and Trail-Making Tests A and B at baseline, 3-years, and 6-years. 
Plasma Klotho levels were measured at 3-year and 6-year visits. It was found that for every 
additional increase in the natural logarithim of Klotho (pg/mL) there was a 35% lower risk of 
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meaningful decline in MMSE. However no statistically significant associations were found 
between Klotho and Trail-Making Tests A or B. It is thought that there was no relationship 
detected in Trail-Making Tests A and B because they solely test executive function and motor 
skills, compared to the MMSE that tests global cognition.105  
Semba et al.,104 analyzed the relationship between plasma Klotho levels and grip strength 
in 804 adults who were 65 years or older enrolled in the InCHIANTI study. Grip strength and 
plasma klotho levels were measures at 3-year, 6-year, and 9-year visits. It was found in the 
unadjusted model that grip strength was positively correlated with plasma Klotho at a threshold 
of <681 pg/mL. Once adjusted for age, sex, education, smoking, physical activity, cognition, and 
chronic disease, plasma Klotho was still found to be significantly associated with grip strength 
(p=0.0009) in adults with plasma Klotho <681 pg/mL, suggesting lower plasma Klotho levels are 
associated with poor musculoskeletal strength.104  
Similarly, Semba et al.,106 examined whether plasma Klotho levels were related to 
prevalent cardiovascular disease in 1,023 adults aged 24 to 102 years using a cross-sectional 
design.  Plasma Klotho levels were found to be associated with age, C-reactive protein, 
cognition, HDL cholesterol, and cardiovascular disease. Researchers then adjusted for 
cardiovascular risk factors (age, sex, smoking, total cholesterol, blood pressure, and diabetes) 
and found the log of plasma Klotho was significantly associated with prevalent cardiovascular 
disease with an odds ration per 1 standard deviation increase equaling 0.85 and a 95% 
confidence interval of 0.72 to 0.99. 106 
Plasma klotho concentrations and knee strength were also analyzed by Semba et al.,107 in 
the Health, Aging, and Body Composition (Health ABC) Study, which is a community-based 
prospective study investigating the impact of changes in weight and body composition on age-
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related physiological and functional changes. Plasma klotho concentrations were measured in 
2,734 older adults, aged 71-80 years, with knee extension strength measured using isokinetic 
dynamometry at baseline, 2-year, and 4-year visits. Participants in the highest tertile of plasma 
Klotho levels were found to have higher knee extension strength at baseline compared with those 
in the lowest tertile, when adjusted for age, sex, race, smoking, study site, C-reactive protein, 
interleukin-6, and diabetes. Participants in the highest tertile of plasma Klotho at baseline were 
also found to have less deterioration in knee strength over the 4 years of follow-up assessments 
compared to those in the lowest tertile.107  
When analyzing the gene sequence of Klotho, there have been single nucleotide 
polymorphisms (SNPs) on exons 2, 3, and 4, as well as in non-coding regions such as the 
promoter region and introns.108,109 These SNPs have been found to be associated with many 
negative health-related outcomes including low bone mineral density, osteoarthritis, high systolic 
blood pressure, atherosclerotic coronary artery disease, cardiometabolic stroke, and high fasting 
glucose.109-119 The greatest understood polymorphism of the Klotho gene is known as KL-VS, 
which contains six SNP sequence variants.109,120 This allele has been observed in association 
with healthy aging in a recent meta-analysis from Di Bona et al.109,121 It has been found to be 
associated with a heterozygous survival advantage over the age of 75, but intriguingly a 
homozygous disadvantage after 75 years due to negative signs and symptoms of coronary artery 
disease, HDL cholesterol, blood pressure, and stroke.109,114,120 KL-VS has also been found to be 
associated with an increased risk of age-related decline of memory, and a lower incidence of the 
genotype in type 1 diabetics, as well as, retinopathy and low levels of inflammatory markers, 
pro-antigenic factors, and adhesion molecules.109,114,115,120 However, the mechanistic pathway by 
which these SNPs display their effects are not fully understood.      
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2.7 Klotho, Obesity, and Aging 
A number of epidemiological studies have linked elevated Klotho levels to improved 
health outcomes and longer lifespan in humans.104-107 These outcomes highlight Klotho as a 
marker of biological age.109  Klotho deficiency has been linked to a number of debilitating age-
related illnesses, suggesting Klotho functions as an integrator of organ systems. Left ventricular 
myopathy has been linked to an imbalance in the FGF23/Klotho complex in patients with 
chronic kidney disease.109,122 Circulating Klotho levels have been found to be inversely related to 
atrial fibrillation in individuals undergoing hemodialysis.109,123 However, the exact mechanism 
by which these outcomes occur is in question. There is potential for Klotho levels to directly 
affect the pathway or phenotype which results in an excessive increase in FGF23 levels leading 
to a decrease in Klotho levels.  As mentioned, Klotho levels also impact pathways including 
insulin/insulin-like growth factor-1, endothelial nitric oxide production, TRPC6, p53/p21, 
cAMP, Wnt, and PKC. 14,98,101 Studies have also linked Klotho to rapamycin (TOR), 
transforming growth factor-β pathways, as well as, mediating anti-inflammatory actions and 
maintenance of calcium balance. 109,124-126 Many of these pathways link Klotho and preservation 
or deterioration of longevity in older adults. However, a potential connection between Klotho 
and aging, is the weight status of an individuals because of the accelerated aging that occurs 
when an individual is overweight or obese.   
Due to the last century’s economic and scientific advances, aging is not the most frequent 
cause of death after the age of 28.127,128 Because individuals live to an average age of 80 years 
old, this leads to a longer physiological aging process promoting changes in cellular function, 
metabolic rearrangements, and structural changes in organs.127,128 Obesity has been recognized to 
promote the aging process by affecting the maturation process of adipose tissue, influencing 
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inflammation and glucose homeostasis, promoting insulin resistance, oxidative stress, DNA 
damage and telomere dysfunction, increased vasomotor tone, increase sympathetic drive, and 
more.127,129 A major concern with the rise in prevalence of obesity, is the health of children. 
Children are presenting with diseases such as arterial hypertension and diabetes mellitus, 
typically found in middle-to-older age individuals. Children who are overweight or obese who do 
not present with disease, still prematurely develop abnormal endothelial cell dysfunction and 
arterial intima-thickening, almost mimicking the aging process in certain physiological 
aspects.11,127,128,130-132 
The pathway that causes accelerated aging in overweight and obesity, may be similar to 
the anti-aging pathway that occurs with increased levels of Klotho. With this, there is evidence 
that weight status affects Klotho levels, with obese and underweight individuals both presenting 
with approximately half the levels of Klotho in the blood compared to those of normal weight,17 
linking obesity with Klotho levels and longevity.  Therefore, it is important to investigate 
whether weight loss in individuals with overweight or obesity will reverse this accelerated aging 
process, as well as increase levels of Klotho.   
2.8 Effect of Physical Activity and Weight Change on Klotho 
As Klotho is linked to longevity as well as cardiovascular and neuroprotective effects, its’ 
relationship to obesity and exercise is important to understand. Amitani et al.,17 investigated 
Klotho’s role in human metabolism by examining the association between plasma Klotho levels 
and BMI (normal weight, underweight/anorexia nervosa, obese). The average BMI for 
participants was 21.84 + 0.36 kg/m2 for normal weight individuals, 13.12 + 0.26 kg/m2 for 
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underweight/anorexia nervosa individuals, and 35.72 + 3.17 kg/m2 for obese individuals. These 
results show mean Klotho levels for participants to be 1391.62 + 144.96 pg/mL for normal 
weight control participants, 764.64 + 65.43 pg/mL for underweight/anorexia nervosa individuals, 
and 847.09 + 111.31 pg/mL for obese individuals, with Klotho levels for underweight and obese 
individuals significantly differing from the normal weight control group. Individuals among the 
underweight/anorexia nervosa group were then put through a weight recovery program, resulting 
in an average BMI of 20.35 + 1.38 kg/m2, which was significantly greater than pre-weight 
recovery program BMI, as well as, in normal BMI range. This weight change also impacted 
Klotho levels, increasing them to 1004.96 + 103.36 pg/mL, which was significantly greater than 
pre-weight recovery Klotho levels, and similar to normal weight control group levels.17   
 Similarly, Ohnishi et al.,19 observed Klotho to be an important mediator of glucose 
metabolism, obesity, and hepatic steatosis. Mice whom had a deficiency in leptin were used 
because of their tendency to develop obesity and hyperglycemia. Klotho function was eliminated 
from certain mice which resulted in reduction of fat accumulation, reduced body weight, and 
suppressed fatty changes in the liver which in turn affected glucose metabolism. However, they 
concluded more research needs to be done to determine the molecular pathway between Klotho 
and obesity to provide insight into the pathobiology of obesity.18,19 
 The influence of exercise on Klotho is important to understand because it has been shown 
to play a key role in lifestyle behavior change for body weight regulation, as well as the 
prevention and treatment of numerous health-related conditions.11,20 Avin et al.,11 suggests an 
overlap in the physiological and functional response between Klotho expression and exercise. 
This was examined in sedentary, young (36.0 + 7.0 years) and old (68.3 + 3.0 years) females, by 
evaluating change in circulating Klotho levels before and after completion of an acute exercise 
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bout, as well as whether completion of an exercise training protocol affects the Klotho response 
to an acute exercise bout.11 Prior to training, no significant changes in the circulating levels of 
Klotho in response to an acute exercise bout was observed.  The younger participants then 
completed a 16-week training program consisting of four to six exercise sessions weekly, with 
the older participants only completing 12-weeks of the same exercise prescriptions. Following 
completion of the training program, there was a significant increase in circulating Klotho levels 
in response to an acute exercise bout in young individuals. Although there was an increase in 
circulating Klotho in response to an acute exercise bout following completion of the training 
program in older individuals, the effect of training was attenuated.11  
 Dalise et al.,21 analyzed a similar relationship between exercise and Klotho in mice. Mice 
were allocated to a low (15 minute), medium (30 minutes), or higher (60 minute) running 
condition at 80% speed from their maximal capacity test. They performed a single running 
session per day, 5 times a week for 4 weeks. This resulted in a significant dose-dependent 
relationship between aerobic exercise and Klotho levels, with the medium condition containing 
double the amount of Klotho in the blood compared to controls, demonstrating a potential up-
regulatory effect cause by exercise training on Klotho levels.21  
 When examining the effect of both obesity and exercise on circulating Klotho levels, 
there appears to be an association. Avin et al.,11 stratified young participants by low BMI (<30 
kg/m2) and high BMI (>30 kg/m2). Individuals in the higher BMI group demonstrated no change 
in circulating Klotho levels following an acute exercise bout at baseline. Following the 16-week 
training program, individuals in the higher BMI group trended towards a significant increase in 
Klotho levels (~30% increase; p=0.06) following an acute exercise bout.11 
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3.0 Methods 
3.1 Methods from Parent Study 
3.1.1  Subjects 
Three hundred eighty-three (383) adults were randomized into 1 of 3 intervention 
conditions described below. For this study, a subsample of subjects who met the following 
criteria were selected and included for this ancillary study and secondary analysis. 
1. Provided blood samples at the baseline, 6-month, and 12-month assessment periods. 
2. Provided all other data at the baseline, 6-month, and 12-month assessment periods. 
3. Were classified as an intervention “responder” (achieved >10% weight loss at both 6 
months and 12 months) or “non-responder” (achieved <5% weight loss at both 6 months 
and 12 months).  
Given the above criteria, 182 (responders = 131, non-responders = 51) of the 383 subjects 
randomized were eligible for this secondary analysis. Additional eligibility and ineligibility 
criteria for the parent study included the following: 
Eligibility Criteria 
1. 18-55 years of age. 
2. Body mass index (BMI) between 25.0 to <40.0 kg/m2. 
3. Ability to provide informed consent prior to participation in this study. 
4. Ability to provide consent from their personal physician to participate in this study. 
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5. The ability to complete the baseline graded exercise test, and clearance from the study 
physician to participate in this study after reviewing the results from this study. 
Ineligibility Criteria 
1. Unable to provide informed consent. 
2. Household member on study staff. 
3. Females who were currently pregnant, breastfeeding in the past 3 months, currently 
lactating, or reporting that she was planning a pregnancy within the next 12 months. 
4. History of bariatric surgery. 
5. Report current medical condition or treatment for a medical condition that could 
affect body weight. These may include the following: cancer (Note: Persons 
previously diagnosed with non-melanoma skin cancers, those successfully treated for 
cancer who have remained disease-free for five years or more were eligible for 
participation in this study); diabetes mellitus; hyperthyroidism; inadequately 
controlled hypothyroidism; chronic renal insufficiency; chronic liver disease; 
gastrointestinal disorders including ulcerative colitis, Crohn’s disease, or 
malabsorption syndromes; etc. 
6. Current congestive heart failure, angina, uncontrolled arrhythmia, symptoms 
indicative of an increased acute risk for a cardiovascular event, prior myocardial 
infarction, coronary artery bypass grafting or angioplasty, conditions requiring 
chronic anticoagulation (i.e. recent or recurrent DVT).  
7. Resting systolic blood pressure of >160 mmHg or resting diastolic blood pressure of 
>100 mmHg, taking medication for blood pressure control, or taking medication that 
can affect blood pressure or heart rate response to exercise (e.g., beta blocker). 
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8. Eating disorders that would contraindicate weight loss or physical activity. 
9. Alcohol or substance abuse. 
10. Currently treated for psychological issues (i.e., depression, bipolar disorder, etc), 
taking psychotropic medications within the previous 12 months, or hospitalized for 
depression within the previous 5 years.  
11. Report exercise >60 minutes per week over the past 3 months. (NOTE: It is important 
that individuals are sedentary when entering this study to allow for maximal effect of 
the intervention.). 
12. Report weight loss of >5% or participating in a weight reduction diet in the past 3 
months. 
13. Report plans to relocate to a location not accessible to the study site or having 
employment, personal, or travel commitments that prohibit attendance to at least 80 
percent of the scheduled intervention sessions and all of the scheduled assessments. 
3.1.2  Recruitment, Screening, and Informed Consent 
Subjects were recruited through advertisements that were approved by the local 
Institutional Review Board. Individuals responding to the advertisements were instructed to call 
the investigators by telephone to obtain further information about the study. Upon receipt of a 
telephone call, staff provided a brief description of the study. Individuals interested in study 
participation after hearing the description, answered questions to determine initial eligibility 
based on the criteria listed above. Individuals who appeared to be eligible based on the initial 
telephone screen were invited to an orientation session where the study was explained to them in 
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greater detail, components of informed consent were explained, and the individuals was given 
the opportunity to ask additional questions to the investigators.  
 Prior to undergoing any experimental procedures for this study, written informed consent 
was obtained from the potential subject, as well as a medical history and physical activity 
readiness questionnaire to confirm that no conditions were present that would exclude the 
participant. Moreover, prior to undergoing any experimental procedures, individuals also 
provided medical clearance from their personal physician stating that it was safe to participate in 
a weight loss intervention that included a reduced energy intake diet and exercise.  
3.1.3  Research Design and Randomization 
Following baseline assessments to confirm eligibility and to collect additional study-
related data, eligible individuals were randomly assigned to one of three weight loss intervention 
conditions. All participants received a behavioral weight loss intervention that included 
attendance at group-based intervention sessions from weeks 1-24 and then every other week 
during weeks 25-52.  In addition, participants received a brief telephone contact with an 
intervention staff member approximately twice per month during weeks 25-52. A brief 
description of the intervention conditions is the following: 
1. DIET: This group was prescribed a diet that reduced energy intake of 1,200-1,800 
kcal/day. No physical activity recommendations were provided to the DIET group. 
2. DIET + PA150: This group was prescribed the same dietary intervention as the DIET 
group. In addition, the DIET+PA150 condition was prescribed a progression to 150 
min/week of unsupervised moderate-to-vigorous intensity physical activity per week.  
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3. DIET+PA250: This group was prescribed the same dietary intervention as the DIET 
group. In addition, the DIET+PA250 condition was prescribed a progression to 250 
min/week of unsupervised moderate-to-vigorous intensity physical activity per week.  
3.1.4  Behavioral Weight Loss Intervention 
Intervention Sessions: Subjects in all intervention conditions were instructed to attend 
weekly weight loss group sessions for weeks 1-24 and approximately every other week during 
weeks 25-52. These groups were closed to only those participants randomly assigned to a 
particular intervention condition (DIET, DIET+PA150, DIET+PA250). These intervention 
sessions focused on behavioral strategies to reduce energy intake and for 
DIET+PA150/DIET+PA250 to also increase exercise consistent with the intervention protocol. 
Sessions were led by a variety of professionals that included exercise physiologists and 
nutritionists. If a group session was missed a brief individual make-up session was offered to 
allow the content to be shared with the subject. Body weight was measured at each of the 
intervention sessions to determine responsiveness of the subject to the weight loss program and 
to provide ongoing feedback. Subjects unable to attend either the group session or the make-up 
session were mailed intervention materials that were distributed to the other subjects at the 
intervention session. 
 In addition to the in-person group sessions, participants received an individual brief 
(approximately 10 minutes in duration) telephone contact from a member of the intervention 
staff approximately twice per month during weeks 25-52 on weeks when an in-person session 
was not scheduled.  This telephone contact was intended to provide an opportunity for individual 
interaction with the intervention staff to assist in understanding of the intervention content and to 
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address barriers to engagement or adherence to the intervention components.  The interventionist 
used a standard script to direct the approach and content of this telephone contact. 
 Diet Intervention: The identical dietary intervention was provided to all subjects 
regardless of randomized intervention assignment (DIET, DIET+PA150, DIET+PA250). This 
included prescribing subjects to consume 1,200-1,800 kcal per day, and to reduce their dietary 
fat intake to 20-30 percent of their total daily energy intake. Initial energy intake as determined 
based on baseline body weight and then adjusted based on weight loss response across the 
intervention. Meal plans, which were developed by registered dietitians, were provided to 
facilitate adoption and compliance with these dietary recommendations. In addition, participants 
self-monitored their dietary intake in a food diary that was returned to the intervention staff at 
each intervention session, with the intervention staff reviewing these diaries and providing 
written feedback relative to self-reported eating behavior.  
 Physical Activity Intervention: By study design the DIET group did not receive 
information about physical activity nor was physical activity prescribed.  The physical activity 
prescription differed between randomized intervention conditions (DIET+PA150 and 
DIET+PA250) as described below.  
Subjects in the DIET+PA150 intervention were instructed to engage in moderate 
intensity physical activity 5 days per week.  The total duration per day began at 20 minutes per 
day and gradually progressed to at least 30 minutes per day.  Physical activity was progressed in 
a gradual manner (5 min/d in 4-week intervals) to maximize adherence and minimize the onset 
of musculoskeletal injuries.  Moderate intensity was prescribed was set using the Borg 15-point 
Rating of Perceived Exertion (RPE) scale, with the range set at 13-15 on this scale. 
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Subjects in the DIET+PA250 intervention were instructed to engage in moderate 
intensity physical activity 5 days per week.  The total duration per day began at 20 minutes per 
day and gradually progressed to at least 50 minutes per day.  Physical activity was progressed in 
a gradual manner (5 min/d in 4-week intervals) to maximize adherence and minimize the onset 
of musculoskeletal injuries.  Moderate intensity was prescribed was set using the Borg 15-point 
Rating of Perceived Exertion (RPE) scale, with the range set at 13-15 on this scale. 
Participants self-monitor physical activity behaviors (MOD-PA and HIGH-PA) in a 
weekly diary provided by the study.  Participants were instructed to return the diary to the 
intervention staff at each in-person visit for review, and the intervention staff provided written 
feedback on the diary prior to it being returned to the participant.  
3.1.5  Assessment Procedures 
Within the parent study that is providing data to address the specific aims as described in 
Chapter 1, outcome data were collected at baseline, 6-months, and following the 12-month 
weight loss intervention. The assessments included measurements of demographic characteristics 
(e.g. race/ethnicity, age, etc.), height, weight, body mass index (BMI), body composition, dietary 
intake, physical activity, cardiorespiratory fitness, and collection of fasting blood samples.  
These data will be used for this ancillary study and secondary data analyses, with the specific 
procedures used to assess the outcomes described below: 
 Height, Weight, and BMI: Weight and height were assessed with the subject clothed in a 
lightweight hospital gown with shoes removed. Weight was assessed using a calibrated digital 
scale to the nearest 0.1 kg with duplicate measures differing by <0.2 kg. Height was assessed 
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using a wall-mounted stadiometer to the nearest 0.1 cm with duplicate measures differing by 
<0.5 cm. Weight and height were used to compute BMI (kg/m2).  
 Body Composition: Total body composition (fat mass, lean mass, percent body fat) was 
measured from a total body scan using a dual-energy x-ray absorptiometry (DXA, GE Lunar 
iDXA, Madision, WI). For this measurement, participants were clothed in a cloth hospital gown 
with metal removed (e.g., rings, watch, earrings, etc.). Women also completed a urine pregnancy 
test to confirm non-pregnancy prior to this measurement.    
 Cardiorespiratory Fitness: Subjects participated in an assessment of cardiorespiratory 
fitness.  Subjects were requested to abstain from vigorous activity for 24 hours prior to the 
assessment period.  American College of Sports Medicine (ACSM)133 criteria were used to 
exclude subjects from this study for whom exercise is contraindicated based on the results of this 
exercise test. 
The speed of the treadmill was kept constant at 3.0 mph (80.4 m/min) with the initial 
grade of the treadmill being 0% and increasing at 1.0% increments at 1-minute intervals.  Heart 
rate during exercise testing was obtained at one-minute intervals using a 12-lead ECG and 
immediately upon termination of the exercise test.  Blood pressure was obtained during each 
even minute (2 min, 4, min, 6 min etc.) and immediately upon termination of the exercise test.  
Rating of perceived exertion was assessed during the final 15 seconds of each minute and at the 
point of test termination.  The test performed to assess cardiorespiratory fitness was a 
submaximal test that was terminated when the participant first achieved or exceeded 85% of their 
age-predicted maximal heart rate (HRMax = 220 minus age).  A physician evaluated the results of 
each exercise test to ensure that exercise training was not contraindicated. 
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Oxygen consumption was measured continuously using a SensorMedics Vmax Encore 
(SensorMedics Corporation, Yorba Linda, CA) metabolic cart, with gas volumes and 
concentrations calibrated according to manufacturer specifications prior to each test.  Fitness is 
expressed in absolute (L/min) and relative terms (ml/kg/min).  Change in cardiorespiratory 
fitness is computed as the difference between these values on the baseline test and on the 
subsequent tests. 
Blood Samples: Blood samples were collected in the morning, between 7:30 AM and 
10:30 AM, with participants instructed to fast with the exception of water, abstain from exercise, 
and abstain from alcohol and smoking for at least 12 hours. This was confirmed prior to blood 
collection. Blood was collected into evacuated tubes, processed in a refrigerated centrifuge, and 
pipetted into 2.0 mL cryovials prior to storage at -80oC. For this study, the stored serum samples 
were used for analysis of Klotho. 
Klotho was measured in duplicate by solid-phase sandwich enzyme-linked 
immunosorbent assay (ELISA) (Immuno-Biological Laboratories, Takasaki, Japan).134 Blood 
samples were analyzed at the University of Pittsburgh McGowan Institute for Regenerative 
Medicine, with intra- and inter-assay coefficients of variation determined for these specific 
Klotho assays. Procedures for the analysis can be found in Appendix A.  
3.2 Data Analysis 
A power analysis was conducted for the parent study that took into account the potential 
for 20% attrition to the randomized sample. The parent study recruited and randomized 383 
participants, which constitutes that overall sample available for this ancillary study.  Based on 
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the criteria for classification as a “responder” or “non-responder”, data from 182 (47.5%) of the 
randomized sample of participants were eligible for this ancillary study and secondary analyses. 
Of the 182 participants, 152 provided blood samples at all three timepoints (see Table 1). 
 
Table 1. Number of participants by randomized intervention condition by weight loss response. 
 
Classification 
Intervention Condition 
DIET DIET+PA150 DIET+250 
N=182    
Responder 43 44 44 
Non-Responder 20 15 16 
 
N=152*    
Responder 37 35 39 
Non-Responder 15 13 13 
*Indicates that blood samples were available for Klotho analysis at 0, 6, and 12 months. 
 
Statistical significance was defined at p<0.05. Statistical analyses were performed using 
Statistical Package for the Social Sciences (SPSS) software, version 25. Data were examined for 
normality prior to analysis, with non-normally distributed data analyzed using non-parametric 
statistical techniques.  
Descriptive baseline data are expressed as either mean + standard deviation or median 
(25th, 75th percentile) for continuous variables and as frequencies for categorical variables. The 
analysis plan listed below: 
1. To examine Specific Aim 1, non-parametric Spearman rank-order correlations 
were performed to assess the association between Klotho and measures of weight, 
obesity status, and cardiorespiratory fitness.  
2. To examine Specific Aim 2, a repeated-measures (treatment X time) analysis of 
variance (ANOVA) was performed to examine change in Klotho concentration by 
intervention condition across the 12-month weight loss intervention.  
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3. To examine Specific Aim 3, to examine the change in Klotho concentration 
across the 12-month behavioral weight loss intervention weight loss response 
(responder vs. non-responder), and to take into account the randomized 
intervention group, a three-factor repeated-measures ANOVA (treatment X 
weight loss response classification X time) was performed. 
4. (Exploratory) To examine the association between baseline Klotho concentration 
and change at either 6 months or 12 months for weight, body composition, or 
cardiorespiratory fitness, Spearman rank order coefficients were performed.  
5. (Exploratory) To examine whether change in weight, change in body 
composition, or change in cardiorespiratory fitness differed by quartile of baseline 
Klotho, and to account for initial randomization condition, a series of three-factor 
repeated-measure ANOVAs (treatment X quartile X time) were performed. 
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4.0 Results 
The primary aim of this study was to examine the change in Klotho concentration across 
behavioral weight loss interventions in adults who were overweight or obese. This was a 
secondary analysis of a 12-month randomized weight loss trial with assessments at baseline, 6 
months, and 12 months. All blood sample processing was performed at the University of 
Pittsburgh McGowan Institute for Regenerative Medicine, with all other study procedures 
(physical assessments, blood collection, and behavioral intervention) being performed at the 
University of Pittsburgh Physical Activity and Weight Management Research Center.    
4.1 Study Participants 
One-hundred eighty-two (182) of three-hundred eighty-three (383) adults from the parent 
study who completed assessments at baseline, 6-, and 12-months and were classified as 
“responders” or “non-responders” to the behavioral interventions were to be included in this 
secondary analysis. One-hundred fifty-two (152) individual’s completed assessments at baseline, 
6-, and 12-months and their serum samples were included in this analysis. Baseline 
characteristics by sample are shown in Table 2. Figure 6 illustrates participants included in the 
secondary analysis.  
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Figure 6. Consort Diagram 
 
Table 2. Baseline Characteristics by Sample 
 
Total Sample (N=383) 
Mean + SD* 
Sample Categorized as 
“Responder” or “Non-
Responder” 
(N=182) 
Mean + SD* 
Sample with Complete 
Blood Samples for Klotho 
Analysis 
(N=152) 
Mean + SD* 
Age (years) 45.0+7.9 45.5+7.9 45.4+8.0 
Weight (kg) 90.9+13.7 91.0+13.6 90.4+13.1 
Body Mass Index (kg/m2) 32.4+3.8 32.3+3.8 32.1+3.7 
Lean Mass (kg) 48.6+8.7 48.5+8.9 48.1+8.7 
Fat Mass (kg) 39.2+8.2 39.3+7.7 39.1+7.8 
Tissue Percent Body Fat (%) 44.5+5.6 44.8+5.5 44.8+5.6 
Region Percent Body Fat (%) 43.2+5.5 43.4+5.4 43.5+5.6 
Cardiorespiratory Fitness (L/min) 2.1+0.5 2.1+0.5 2.1+0.5 
Cardiorespiratory Fitness 
(ml/kg/min) 
22.6+4.4 22.7+4.6 22.9+4.5 
Cardiorespiratory Fitness 
(Termination Time - minutes) 
7.7+3.0 7.9+3.0 8.0+3.0 
Female (N,%) 304, 79.4% 141, 77.5% 118, 77.6% 
Non-White (N,%) 104, 27.2% 44, 24.2% 36, 23.7% 
*SD – Standard deviation 
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4.2 Change in Key Variables Across the 12-Month Intervention 
Analyses were conducted to examine the impact the behavioral weight loss intervention, 
and response to the intervention (“responder” vs. “non-responder”), had on key variables that 
included measures of weight, body composition, and cardiorespiratory fitness. Separate three-
factor repeated-measure ANOVA’s (treatment X weight loss response classification X time) 
were performed for each of these variables. Results are presented in Tables 3-10.  
Analysis revealed body weight significantly decreased across time (p=0.000), with no 
significant difference between treatment conditions (p=0.606). However, by definition weight 
loss was significantly different by weight loss response classification (p=0.001), with 
“responders” losing a greater amount of weight compared to “non-responders” (Table 3). 
Similarly, body mass index significantly decreased across time (p=0.000), with no significant 
difference between treatment conditions (p=0.128). Body mass index was significantly different 
by weight loss response classification (p=0.000), with individuals in the “responder” 
classification having a greater decrease in BMI across the 12-month intervention compared to 
“non-responders” (Table 4).  
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Table 3. Change in body weight (kg) by treatment condition and weight loss response (responder vs. non-responder) 
Treatment Category 
Body Weight (kg) p-values 
Baseline 6 Months 12 Months Treatment Category Time Treatment x Time 
Category  
X Time 
Category X 
Treatment 
X Time 
DIET 
(N=52) 
Non-Responder 
(N=15) 90.4+9.2 89.6+10.4 91.9+11.5 
0.606 
 
0.001 
 
0.000 
 
0.328 
 
0.000 
 
0.355 
 
 Responder 
(N=37) 91.3+14.3 77.6+11.5 74.9+11.7 
DIET+150 
(N=48) 
Non-Responder 
(N=13) 87.9+17.6 86.1+18.0 86.7+18.3 
 Responder 
(N=35) 91.8+11.0 76.2+9.3 73.8+10.4 
DIET+250 
(N=52) 
Non-Responder 
(N=13) 87.5+10.7 86.1+10.1 86.6+9.8 
 Responder 
(N=39) 89.9+14.6 76.1+13.3 74.0+12.9 
 
 
Table 4. Change in body mass index (kg/m2) by treatment condition and weight loss response (responder vs. non-responder) 
Treatment Category 
Body Mass Index (kg/m2) p-values 
Baseline 6 Months 12 Months Treatment Category Time Treatment x Time 
Category  
X Time 
Category X 
Treatment 
X Time 
DIET 
(N=52) 
Non-Responder 
(N=15) 33.2+3.3 32.9+3.8 33.7+4.0 
0.128 
 
0.000 
 
0.000 
 
0.176 
 
0.000 
 
0.274 
 
 Responder 
(N=37) 32.1+3.1 27.3+3.0 26.2+2.7 
DIET+150 
(N=48) 
Non-Responder 
(N=13) 31.1+3.8 30.4+3.8 30.6+4.0 
 Responder 
(N=35) 32.7+3.5 27.2+3.2 26.3+3.3 
DIET+250 
(N=52) 
Non-Responder 
(N=13) 30.9+4.1 30.4+3.8 30.6+3.6 
 Responder 
(N=39) 31.8+4.1 26.9+3.8 26.2+3.7 
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For measures of body composition, lean mass significantly decreased across the 12-month intervention (p=0.000), with no 
difference by treatment conditions (p=0.724). Moreover, lean mass was significantly different by weight loss response across time 
(p=0.000), with individuals in the “responder” classification having a greater decrease in lean mass compared to individuals in the 
“non-responder” classification over the 12-month intervention (Table 5). 
 
Table 5. Change in lean mass (kg) by treatment condition and weight loss response (responder vs. non-responder) 
Treatment Category 
Lean Mass (kg) p-values 
Baseline 6 Months 12 Months Treatment Category Time Treatment x Time 
Category  
X Time 
Category X 
Treatment 
X Time 
DIET (N=52) Non-Responder 
(N=15) 46.3+ 4.5 46.4+ 5.0 47.0+ 4.5 
0.724 0.872 0.000 0.490 0.000 0.087 
 Responder 
(N=37) 48.8+ 10.3 46.3+ 9.2 46.3+ 9.5 
DIET+150 
(N=48) 
Non-Responder 
(N=13) 48.5+ 1.3 48.8+ 1.4 47.9+ 12.8 
 Responder 
(N=35) 49.0+ 8.3 46.6+ 7.6 46.6+ 7.5 
DIET+250 
(N=52) 
Non-Responder 
(N=13) 46.8+ 8.7 46.6+ 1.3 46.3+ 8.9 
 Responder 
(N=39) 47.4+ 7.4 45.6+ 7.5 45.5+ 7.2 
 
  Fat mass significantly decreased across the 12-month intervention (p=0.000) with no difference by treatment conditions 
(p=0.159). However, fat mass was significantly different by weight loss response (p=0.000), with “responders” losing a greater 
amount of fat mass compared to “non-responders” over the 12-month intervention (Table 6).  Similarly, percent body fat mass 
significantly decreased across time (p=0.000), with no difference by treatment condition (p=0.187). Percent fat mass was significantly 
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different by weight loss response (p=0.000), with “responders” losing a greater percent of fat mass across the 12-month intervention 
compared to “non-responders” (Table 7).    
 
Table 6. Change in fat mass (kg) by treatment condition and weight loss response (responder vs. non-responder) 
Treatment Category 
Fat Mass (kg) p-values 
Baseline 6 Months 12 Months Treatment Category Time Treatment x Time 
Category  
X Time 
Category X 
Treatment 
X Time 
DIET 
(N=52) 
Non-Responder 
(N=15) 41.0+ 5.0 40.1+5.9 42.3+ 7.1  
0.159 
 
0.000 
 
0.000 
 
0.254 
 
0.000 
 
0.536 
 
 Responder 
(N=37) 39.2+ 6.4 28.3+5.9 25.3+ 6.1 
DIET+150 
(N=48) 
Non-Responder 
(N=13) 36.3+ 7.1 34.3+ 6.7 35.6+ 8.0 
 Responder 
(N=35) 39.6+ 7.2 26.7+ 7.7 24.4+ 7.9 
DIET+250 
(N=52) 
Non-Responder 
(N=13) 37.7+ 8.9  36.5+ 8.9 37.2+ 8.6 
 Responder 
(N=39) 38.5+ 7.2 27.6+ 9.5 25.8+ 9.3 
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Table 7. Change in percent body fat by treatment condition and weight loss response (responder vs. non-responder) 
Treatment Category 
Region Percent Body Fat (%) p-values 
Baseline 6 Months 12 Months Treatment Category Time Treatment x Time 
Category  
X Time 
Category X 
Treatment 
X Time 
DIET 
(N=52) 
Non-Responder 
(N=15) 45.5+2.0 44.9+2.1 45.8+2.6 
0.187 
 
0.000 
 
0.000 
 
0.337 
 
0.000 
 
0.823 
 
 Responder 
(N=37) 43.4+4.8 36.8+6.0 34.2+6.4 
DIET+150 
(N=48) 
Non-Responder 
(N=13) 41.9+5.9 40.4+6.0 41.7+6.1 
 Responder 
(N=35) 43.3+6.1 34.9+8.2 32.8+8.0 
DIET+250 
(N=52) 
Non-Responder 
(N=13) 43.2+7.5 42.5+7.9 43.2+7.9 
 Responder 
(N=39) 43.5+6.0 35.7+8.0 34.2+7.7 
 
 
Data for measures of cardiorespiratory fitness are shown in Tables 8-10. There were no significant changes in absolute 
cardiorespiratory fitness (L/min) across time, by intervention group or weight loss response classification, and no group by time or 
classification by time effects (Table 8). However, there was a significant increase in relative cardiorespiratory fitness (ml/kg/min) 
across the 12-month intervention (p=0.000). Relative cardiorespiratory fitness (ml/kg/min) differed by intervention group (p=0.014), 
with individuals in the DIET+PA250 group having the greatest increase in fitness levels, then the DIET+PA150 group, followed by 
the DIET group. Further, there was a significant difference by weight loss response (p=0.000), with “responders” having greater 
increases in cardiorespiratory fitness level (ml/kg/min) across the 12-month intervention compared to “non-responders” (Table 9). A 
similar pattern of response was observed when test termination time was used to represent cardiorespiratory fitness (Table 10). 
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Table 8. Change in absolute cardiorespiratory fitness (L/min) by treatment condition and weight loss response (responder vs. non-responder) 
Treatment Category 
Cardiorespiratory Fitness (L/min) p-values 
Baseline 6 Months 12 Months Treatment Category Time Treatment x Time 
Category  
X Time 
Category X 
Treatment 
X Time 
DIET (N=51) Non-Responder 
(N=14) 2.0+0.5 1.9+0.4 1.8+0.4 
0.826 
 
0.147 
 
0.052 
 
0.122 
 
0.720 
 
0.625 
 
 Responder 
(N=37) 2.1+0.6 2.0+0.5 2.0+0.5 
DIET+150 
(N=45) 
Non-Responder 
(N=11) 1.9+0.5 1.9+0.6 1.9+0.5 
 Responder 
(N=34) 2.1+0.5 2.2+0.5 2.1+0.5 
DIET+250 
(N=51) 
Non-Responder 
(N=12) 2.0+0.5 2.0+0.5 2.0+0.5 
 Responder 
(N=39) 2.1+0.5 2.1+0.5 2.1+0.5 
 
 
Table 9. Change in relative cardiorespiratory fitness (ml/kg/min) by treatment condition and weight loss response (responder vs. non-responder) 
Treatment Category 
Cardiorespiratory Fitness (ml/kg/min) p-values 
Baseline 6 Months 12 Months Treatment Category Time Treatment x Time 
Category  
X Time 
Category X 
Treatment 
X Time 
DIET 
(N=51) 
Non-Responder 
(N=14) 21.9+5.1 21.8+4.2 20.0+4.1 
0.111 
 
0.000 
 
0.000 
 
0.014 
 
0.000 
 
0.448 
 
 Responder 
(N=37) 22.8+4.4 25.3+4.4 26.1+4.7 
DIET+150 
(N=45) 
Non-Responder 
(N=11) 23.1+5.4 23.6+6.0 23.2+5.4 
 Responder 
(N=34) 23.3+4.7 28.6+6.8 29.3+6.1 
DIET+250 
(N=51) 
Non-Responder 
(N=12) 23.2+4.5 23.0+5.3 22.8+4.9 
 Responder 
(N=39) 22.9+3.9 27.4+4.8 27.9+4.7 
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Table 10. Change in cardiorespiratory fitness (minutes) by treatment condition and weight loss response (responder vs. non-responder) 
Treatment Category 
Cardiorespiratory Fitness (min) p-values
Baseline 6 Months 12 Months Treatment Category Time Treatment x Time 
Category  
X Time 
Category X 
Treatment 
X Time 
DIET 
(N=52) 
Non-Responder 
(N=15) 6.9+2.3 7.8+2.3 6.4+2.1 
0.032 0.001 0.000 0.042 0.000 0.053 
Responder 
(N=37) 7.7+2.8 9.8+3.1 89.6+3.1 
DIET+150 
(N=47) 
Non-Responder 
(N=12) 8.1+3.9 8.7+3.6 9.1+3.7 
Responder 
(N=35) 8.3+3.3 11.9+4.2 11.9+4.0 
DIET+250 
(N=52) 
Non-Responder 
(N=13) 8.9+3.1 9.1+3.7 7.7+2.8 
Responder 
(N=39) 8.0+2.6 11.3+3.1 11.4+2.8 
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4.3 Klotho Response 
4.3.1  Specific Aim 1: Associations Between Klotho Concentration and Measures of Weight, 
Body Mass Index, Body Composition, and Cardiorespiratory Fitness 
Analyses were conducted to examine the association between Klotho concentration and 
corresponding measures of weight, body mass index, body composition, and cardiorespiratory 
fitness. A Spearman rank-order correlation coefficient was performed for each variable (N=152; 
cardiorespiratory fitness: N=150). A non-parametric test was used due to skewness and slight 
kurtosis in Klotho concentration. Results are presented in Table 11. 
At baseline, Klotho concentration was found to be inversely associated with lean body 
mass (p=0.021), with a lower lean mass associated with higher Klotho levels. Further, baseline 
Klotho concentration was inversely associated with absolute cardiorespiratory fitness (p=0.042), 
with a lower cardiorespiratory fitness level associated with a higher Klotho concentration. 
However, at baseline there were no significant associations between Klotho concentration and 
weight, BMI, fat mass, percent body fat, relative cardiorespiratory fitness, or cardiorespiratory 
fitness test time. 
 At 6 months, Klotho concentration was inversely associated with lean body mass 
(p=0.005), with a lower lean body mass being associated with a higher Klotho concentration. 
Moreover, Klotho concentration was significantly associated with percent body fat at 6 months 
(p=0.019), with a greater percent body fat being associated with a higher Klotho concentration. 
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However, at 6 months there were no significant associations between Klotho concentration and 
weight, BMI, fat mass, or cardiorespiratory fitness.  
At 12 months, Klotho concentration was only found to be inversely associated to lean 
body mass (p=0.020), with less lean mass being associated with higher Klotho levels. There were 
no significant associations found at 12 months between Klotho concentration and measures of 
weight, BMI, fat mass, percent body fat, or cardiorespiratory fitness.  
Table 11. Correlation between Klotho and corresponding measures of weight, body mass index, body 
composition, and cardiorespiratory fitness 
Variable Assessment 
Period 
Klotho (pg/mL) 
Baseline 6 Months 12 Months 
Body Weight (kg) Baseline r= -0.121 (p=0.136) ----- ----- 
6 Months ----- r= -0.137 (p=0.093) ----- 
12 Months ----- ----- r= -0.147 (p=0.070) 
Body Mass Index (kg/m2) Baseline r= -0.103 (p=0.208) ----- ----- 
6 Months ----- r= -0.012 (p=0.881) ----- 
12 Months ----- ----- r= -0.112 (p=0.168) 
Lean Mass (kg) Baseline r= -0.188 (p=0.021) ----- ----- 
6 Months ----- r= -0.229 (p=0.005) ----- 
12 Months ----- ----- r= -0.188 (p=0.020) 
Fat Mass (kg) Baseline r=0.021 (p=0.797) ----- ----- 
6 Months ----- r=0.072 (p=0.379) ----- 
12 Months ----- ----- r= -0.014 (p=0.867) 
Region Percent Body Fat Baseline r=0.129  (p=0.114) ----- ----- 
6 Months ----- r=0.191 (p=0.019) ----- 
12 Months ----- ----- r=0.088 (p=0.281) 
Absolute Cardiorespiratory 
Fitness (L/min) 
Baseline r= -0.165 (p=0.042) ----- ----- 
6 Months ----- r= -0.125 (p=0.129) ----- 
12 Months ----- ----- r= -0.122 (p=0.140) 
Relative Cardiorespiratory 
Fitness (ml/kg/min) 
Baseline r= -0.074 (p=0.367) ----- ----- 
6 Months ----- r= -0.066 (p=0.425) ----- 
12 Months ----- ----- r= --0.015 (p=0.856) 
Cardiorespiratory Fitness 
(minutes) 
Baseline r= -0.042 (p=0.607) ----- ----- 
6 Months ----- r= -0.117 (p=0.151) ----- 
12 Months ----- ----- r= -0.050 (p=0.539) 
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4.3.2  Specific Aim 2: Examine the Change in Klotho Concentration by Intervention Group 
Across Time 
A Repeated-measures ANOVA was conducted to examine the change in Klotho 
concentration by intervention group across the 12-month weight loss intervention (Table 12 and 
Figure7). A significant change in Klotho concentration across time (p=0.009) was observed, with 
Klotho concentration increasing at 6 months followed by a decrease in concentration at 12-
months. However, there was no significant difference by intervention group (p=0.345), nor was 
there a significant treatment X time effect (p=0.329) across the 12-month intervention.  
Table 12. Mean change in Klotho concentration by intervention condition and weight loss classification across 
the 12-month behavioral weight loss intervention 
Timepoint 
Mean + SD P-Value
Condition Baseline 6 Months 12 Months Time Treatment Treatment x 
Time 
DIET 
N=52 900.4+411.7 942.4+449.3 863.2+377.6 
0.009 0.345 0.329 
DIET+PA150 
N=48 898.6+327.8 979.7+445.0 944.1+409.1 
DIET+PA250 
N=52 998.7+392.7 1031.6+460.6 1014.0+471.7 
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Figure 7. Change in mean Klotho concentration by intervention group across the 12-month behavioral weight 
loss intervention. 
4.3.3  Specific Aim 3: Examine the Change in Klotho Concentration by Intervention Group 
and Weight Loss Classification Across Time 
Analyses were conducted to examine the change in Klotho concentration across the 12-
month behavioral weight loss intervention by intervention group and by weight loss response 
classification. Analyses performed was a three-factor repeated-measures ANOVA (treatment X 
weight loss response classification X time) to account for the randomized intervention group 
assignments, with results presented in Table 13.  There were no significant differences by weight 
loss response (p=0.477). Moreover, the weight loss response X time (p=0.284), and treatment X 
classification X time effects (p=0.748) was not statistically significant.  
P-Value:
Time: 0.009 
Treatment: 0.345 
Treatment*Time: 
0.329 
55 
Table 13. Change in Klotho (pg/mL) by treatment condition and weight loss response (responder vs. non-responder) 
Treatment Category 
Klotho (pg/mL) p-values
Baseline 6 Months 12 Months Treatment Category Time Treatment x Time 
Category  
X Time 
Category X 
Treatment 
X Time 
DIET 
(N=52) 
Non-
Responder 
(N=15) 
1051.1+562.1 1055.6+553.7 943.3+413.1 
0.538 0.477 0.094 0.216 0.284 0.748 
Responder 
(N=37) 839.3+322.4 896.5+399.0 830.7+363.2 
DIET+150 
(N=48) 
Non-
Responder 
(N=13) 
750.0+257.1 784.7+277.6 805.8+276.1 
Responder 
(N=35) 953.7+337.0 1052.2+476.0 995.5+440.9 
DIET+250 
(N=52) 
Non-
Responder 
(N=13) 
958.0+339.4 936.9+309.3 933.7+480.2 
Responder 
(N=39) 1012.3+412.2 1063.2+500.4 1040.7+472.1 
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4.3.4  (Exploratory) Baseline Klotho Concentration to Predict Change in Weight, Body 
Composition, and Cardiorespiratory Fitness by Intervention Group and Weight 
Loss Classification 
Exploratory analyses were conducted to examine whether baseline Klotho concentration 
is associated with measures of change at either 6 months or 12 months for weight, body 
composition, or cardiorespiratory fitness. Spearman rank order coefficients were computed, with 
results presented in Table 14. No significant correlations were found between baseline Klotho 
concentration and change in weight, change in body composition, or change in cardiorespiratory 
fitness.  
Table 14. Correlation between Baseline Klotho and change in weight, body composition, and 
cardiorespiratory fitness 
Variable Baseline Klotho 
Body Weight (kg)           Change from Baseline to 6 Months* 
 Change from Baseline to 12 Months** 
r=0.064 (p=0.430) 
r=0.013 (p=0.878) 
Lean Mass (kg)             Change from Baseline to 6 Months* 
    Change from Baseline to 12 Months** 
r=0.188 (p=0.147) 
r=0.125 (p=0.124) 
Fat Mass (kg)                 Change from Baseline to 6 Months* 
 Change from Baseline to 12 Months** 
r=0.031 (p=0.708) 
r= -0.015 (p=0.856) 
Percent Body Fat          Change from Baseline to 6 Months* 
 Change from Baseline to 12 Months** 
r=0.019 (p=0.817) 
r= -0.013 (p=0.869) 
Absolute Cardiorespiratory Fitness (L/min)              Change from Baseline to 6 Months* 
 Change from Baseline to 12 Months** 
r=0.126 (p=0.125) 
r=0.079 (p=0.337) 
Relative Cardiorespiratory Fitness (ml/kg/min)         Change from Baseline to 6 Months* 
 Change from Baseline to 12 Months** 
r=0.103 (p=0.211) 
r=0.042 (p=0.614) 
Cardiorespiratory Fitness (minutes)          Change from Baseline to 6 Months* 
 Change from Baseline to 12 Months** 
r= -0.034 (p=0.679) 
r= -0.051 (p=0.536) 
*Indicates change computed as Month 6 – Baseline
**Indicates change computed as Month 12 – Baseline
57 
Analyses were also conducted to examine whether change in Klotho concentration at 6 
months was associated with measures of change at 6 months for weight, body composition, or 
cardiorespiratory fitness. Spearman rank order correlation coefficients were computed, with 
results presented in Table 15. No significant correlations were observed between change in 
Klotho concentration at 6 months and change in weight, change in body composition, or change 
in cardiorespiratory fitness at 6 months. 
Table 15. Correlation between change in Klotho at 6 months and change in weight, body composition, and 
cardiorespiratory fitness at 6 months 
Variable  Baseline Klotho 
Body Weight (kg)                                                                  Change from Baseline to 6 Months* r= -0.106 (p=0.194) 
 
Lean Mass (kg)                                                                      Change from Baseline to 6 Months* r= -0.030 (p=0.718) 
 
Fat Mass (kg)                                                                         Change from Baseline to 6 Months* r= -0.113 (p=0.166) 
 
Percent Body Fat                                                                   Change from Baseline to 6 Months* r= -0.072 (p=0.381) 
 
Absolute Cardiorespiratory Fitness (L/min)                         Change from Baseline to 6 Months* r= -0.095 (p=0.246) 
 
Relative Cardiorespiratory Fitness (ml/kg/min)                    Change from Baseline to 6 Months* r= -0.003 (p=0.711) 
 
Cardiorespiratory Fitness (minutes)                                      Change from Baseline to 6 Months* r= -0.015 (p=0.856) 
 
*Indicates change computed as Month 6 – Baseline 
 
Further, analyses were conducted to examine whether change in Klotho concentration at 
12 months was associated with measures of change at 12 months for weight, body composition, 
or cardiorespiratory fitness. Spearman rank order correlation coefficients were computed, with 
results presented in Table 16. No significant correlations were observed between change in 
Klotho concentration at 12 months and change in weight, change in body composition, or change 
in cardiorespiratory fitness at 12 months. 
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Table 16. Correlation between change in Klotho at 12 months and change in weight, body composition, and 
cardiorespiratory fitness at 12 months 
Variable  Baseline Klotho 
Body Weight (kg)                                                              Change from Baseline to 12 Months** r= -0.023 (p=0.781) 
 
Lean Mass (kg)                                                                  Change from Baseline to 12 Months** r= -0.068 (p=0.404) 
 
Fat Mass (kg)                                                                     Change from Baseline to 12 Months** r= -0.020 (p=0.809) 
 
Percent Body Fat                                                               Change from Baseline to 12 Months** r= -0.037 (p=0.652) 
 
Absolute Cardiorespiratory Fitness (L/min)                     Change from Baseline to 12 Months** r=0.009 (p=0.918) 
 
Relative Cardiorespiratory Fitness (ml/kg/min)                Change from Baseline to 12 Months** r=0.064 (p=0.437) 
 
Cardiorespiratory Fitness (minutes)                                  Change from Baseline to 12 Months** r= -0.069 (p=0.399) 
 
**Indicates change computed as Month 12 – Baseline 
 
Further exploratory analyses were performed to examine whether change in weight, 
change in body composition, and change in cardiorespiratory fitness differed by quartile of 
baseline Klotho. Quartiles were defined as Quartile 1: 0-638 pg/mL, Quartile 2: 639-877 pg/mL, 
Quartile 3: 878-1117 pg/mL, and Quartile 4: >1118 pg/mL. Three-factor repeated-measure 
ANOVA’s (treatment X quartile X time) were performed for each variable (see Tables 17-24). 
These analyses were repeated for only “responders” and a similar pattern to the full sample was 
observed (see Appendix B: Tables 26-34).  
Analysis revealed body weight significantly decreased across time (p=0.000), with no 
significant difference by treatment conditions (p=0.604) or quartile (p=0180) (Table 17). 
Similarly, body mass index significantly decreased across time (p=0.000), with no significant 
difference by treatment condition (p=0.402) or quartile (p=0.140). However, there was a 
significant treatment X quartile X time effect (p=0.044) across the 12-month intervention (Table 
18).  
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Table 17. Change in Weight (kg) by treatment condition and Quartile of Baseline Klotho 
Treatment 
Baseline 
Klotho 
Quartile 
Weight (kg) p-values 
Baseline 
Change 
from 
Baseline 
to  
6 Months 
Change 
from 
Baseline to 
12 Months 
Treatment 
Baseline 
Klotho 
Quartile 
Time Treatment X Time 
Baseline 
Klotho 
Quartile 
X Time 
Baseline 
Klotho 
Quartile X 
Treatment 
X Time 
DIET 
(N=52) 
Quartile 1 
(N=38) 93.8+13.2 -12.1+7.0 -14.3+10.2 
0.604             0.180 0.000 0.176 0.985 0.057 
 Quartile 2 
(N=38) 85.7+7.7 -8.5+6.8 -9.6+9.4 
 Quartile 3 
(N=38) 90.8+16.9 -10.8+7.3 -11.8+10.8 
 Quartile 4 
(N=38) 92.0+10.4 -6.7+6.5 -8.1+9.8 
DIET+150 
(N=48) 
Quartile 1 
(N=38) 92.2+13.7 -10.3+8.0 -11.4+8.9 
 Quartile 2 
(N=38) 95.0+11.1 -15.1+7.6 -16.4+7.9 
 Quartile 3 
(N=38) 87.8+15.9 -8.8+6.9 -10.3+9.7 
 Quartile 4 
(N=38) 88.7+8.1 -16.0+6.8 -18.6+8.0 
DIET+250 
(N=52) 
Quartile 1 
(N=38) 93.7+16.6 -10.3+8.9 -12.7+12.5 
 Quartile 2 
(N=38) 93.2+12.6 -11.0+6.8 -11.7+9.0 
 Quartile 3 
(N=38) 80.2+9.8 -12.6+5.2 -13.1+5.3 
 Quartile 4 
(N=38) 88.5+14.1 -9.7+5.5 -11.9+6.7 
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Table 18. Change in Body Mass Index (kg/m2) by treatment condition and Quartile of Baseline Klotho 
Treatment 
Baseline 
Klotho 
Quartile 
Body Mass Index (kg/m2) p-values 
Baseline 
Change 
from 
Baseline 
to  
6 Months 
Change 
from 
Baseline to 
12 Months 
Treatment 
Baseline 
Klotho 
Quartile 
Time Treatment X Time 
Baseline 
Klotho 
Quartile X 
Time 
Baseline 
Klotho 
Quartile X 
Treatment 
X Time 
DIET 
(N=52) 
Quartile 1 
(N=38) 33.1+3.5 -4.1+0.7 -4.9+1.0 
0.402 0.140 0.000 0.117 0.975 0.044 
 Quartile 2 
(N=38) 31.5+3.0 -3.1+1.0 -3.5+1.7 
 Quartile 3 
(N=38) 31.8+3.1 -3.7+0.8 -4.1+1.9 
 Quartile 4 
(N=38) 32.9+3.0 -2.3+1.3 -2.9+2.0 
DIET+150 
(N=48) 
Quartile 1 
(N=38) 32.2+3.6 -3.6+0.4 -4.0+0.8 
 Quartile 2 
(N=38) 33.3+3.6 -5.4+0.2 -5.9+0.1 
 Quartile 3 
(N=38) 31.7+4.5 -3.1+0.5 -3.7+0.2 
 Quartile 4 
(N=38) 32.1+2.4 -5.7+0.4 -6.6+0.6 
DIET+250 
(N=52) 
Quartile 1 
(N=38) 34.1+4.5 -3.7+1.1 -4.6+0.1 
 Quartile 2 
(N=38) 32.2+3.8 -3.8+0.2 -4.1+0.3 
 Quartile 3 
(N=38) 29.2+2.8 -4.6+0.3 -4.7+0.5 
 Quartile 4 
(N=38) 31.4+4.4 -3.5+0.1 -4.3+0.2 
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For measures of body composition, data revealed lean mass significantly decreased 
across the 12-month intervention (p=0.000), with no significant differences by treatment 
condition (p=0.567) or quartile (p=0.539) (Table 19). Similarly, fat mass significantly decreased 
over time (p=0.000), with no significant differences by treatment condition (p=0.237) or quartile 
(p=0.207) (Table 20). A similar pattern of response was observed with percent body fat, with a 
significant decrease across the 12-month intervention (p=0.000) (Table 21). However, there was 
a significant treatment X quartile X time effect (p=0.022) for percent body fat revealed.
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Table 19. Change in Lean Mass (kg) by treatment condition and Quartile of Baseline Klotho 
Treatment 
Baseline 
Klotho 
Quartile 
Lean Mass (kg) p-values 
Baseline 
Change 
from 
Baseline 
to  
6 Months 
Change 
from 
Baseline to 
12 Months 
Treatment 
Baseline 
Klotho 
Quartile 
Time Treatment X Time 
Baseline 
Klotho 
Quartile X 
Time 
Baseline 
Klotho 
Quartile X 
Treatment 
X Time 
DIET 
(N=52) 
Quartile 1 
(N=38) 50.6+9.4 -2.2+1.9 -2.1+2.0 
0.567 0.539 0.000 0.551 0.545 0.075 
 Quartile 2 
(N=38) 44.3+3.9 -1.5+1.6 -1.4+1.8 
 Quartile 3 
(N=38) 48.7+11.5 -2.2+2.1 -2.0+2.4 
 Quartile 4 
(N=38) 46.5+7.7 -0.8+1.7 -0.7+1.7 
DIET+150 
(N=48) 
Quartile 1 
(N=38) 51.3+11.2 -1.4+2.2 -1.7+2.3 
 Quartile 2 
(N=38) 51.4+9.1 -2.2+2.2 -2.7+2.6 
 Quartile 3 
(N=38) 46.3+8.8 -0.9+1.5 -1.0+1.6 
 Quartile 4 
(N=38) 46.5+8.5 -2.9+2.3 -2.6+2.6 
DIET+250 
(N=52) 
Quartile 1 
(N=38) 45.6+5.5 -1.5+2.0 -1.7+2.3 
 Quartile 2 
(N=38) 50.3+8.8 -2.3+1.6 -2.2+2.3 
 Quartile 3 
(N=38) 44.4+4.7 -1.0+1.3 -0.8+0.8 
 Quartile 4 
(N=38) 46.3+7.7 -0.8+1.3 -1.2+1.4 
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Table 20. Change in Fat Mass (kg) by treatment condition and Quartile of Baseline Klotho 
Treatment 
Baseline 
Klotho 
Quartile 
Fat Mass (kg) p-values 
Baseline 
Change 
from 
Baseline 
to  
6 Months 
Change 
from 
Baseline to 
12 Months 
Treatment 
Baseline 
Klotho 
Quartile 
Time Treatment X Time 
Baseline 
Klotho 
Quartile 
X Time 
Baseline 
Klotho 
Quartile X 
Treatment 
X Time 
DIET 
(N=52) 
Quartile 1 
(N=38) 39.8+7.3 -9.7+5.3 -11.8+8.7 
0.237 0.207 0.000 0.137 0.987 0.096 
 Quartile 2 
(N=38) 38.3+4.1 -6.8+5.2 -7.8+7.7 
 Quartile 3 
(N=38) 39.0+6.4 -8.6+5.9 -9.7+9.0 
 Quartile 4 
(N=38) 42.1+4.4 -5.4+4.7 -7.0+8.0 
DIET+150 
(N=48) 
Quartile 1 
(N=38) 37.6+5.3 -8.7+6.3 -9.5+7.5 
 Quartile 2 
(N=38) 40.2+5.9 -12.5+6.2 -13.1+7.4 
 Quartile 3 
(N=38) 38.5+10.6 -7.7+5.8 -9.0+8.6 
 Quartile 4 
(N=38) 39.1+4.9 -12.8+5.5 -15.4+6.4 
DIET+250 
(N=52) 
Quartile 1 
(N=38) 44.8+12.3 -8.7+6.9 -10.7+10.2 
 Quartile 2 
(N=38) 39.7+10.7 -8.4+5.2 -9.2+7.0 
 Quartile 3 
(N=38) 32.8+6.6 -11.4+4.3 -11.9+5.2 
 Quartile 4 
(N=38) 39.0+8.2 -8.5+5.0 -10.3+1.2 
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Table 21. Change in Percent Fat Mass (%) by treatment condition and Quartile of Baseline Klotho 
Treatment 
Baseline 
Klotho 
Quartile 
Percent Fat Mass (%) p-values 
Baseline 
Change 
from 
Baseline 
to  
6 Months 
Change 
from 
Baseline to 
12 Months 
Treatment 
Baseline 
Klotho 
Quartile 
Time Treatment X Time 
Baseline 
Klotho 
Quartile X 
Time 
Baseline 
Klotho 
Quartile X 
Treatment 
X Time 
DIET 
(N=52) 
Quartile 1 
(N=38) 42.7+5.3 -5.9+2.5 -7.7+3.6 
0.158 0.400 0.000 0.094 0.884 0.022 
 Quartile 2 
(N=38) 45.0+1.7 -4.4+2.1 -5.5+3.9 
 Quartile 3 
(N=38) 43.5+3.8 -5.3+1.9 -7.0+4.2 
 Quartile 4 
(N=38) 46.2+3.8 -3.1+0.9 -4.5+1.6 
DIET+150 
(N=48) 
Quartile 1 
(N=38) 41.4+5.4 -5.9+2.9 -6.6+3.6 
 Quartile 2 
(N=38) 42.7+5.8 -8.2+2.3 -8.9+2.8 
 Quartile 3 
(N=38) 43.6+6.9 -4.9+0.9 -6.2+1.6 
 Quartile 4 
(N=38) 44.6+6.0 -8.3+2.3 -10.9+2.2 
DIET+250 
(N=52) 
Quartile 1 
(N=38) 47.5+5.4 -4.5+0.9 -6.2+3.5 
 Quartile 2 
(N=38) 42.6+8.2 -4.9+0.9 -5.7+1.9 
 Quartile 3 
(N=38) 41.0+4.2 -9.6+1.8 -10.0+1.4 
 Quartile 4 
(N=38) 44.2+5.0 -5.9+2.4 -7.1+2.3 
 
Data for measures of cardiorespiratory fitness are shown in Tables 22 – 24. There was a significant difference in absolute 
cardiorespiratory fitness (L/min) by treatment condition across the 12-month intervention (p=0.036), with no significant difference by 
quartile (p=0.719) (Table 22). Moreover, relative cardiorespiratory fitness revealed a significant increase across time (p=0.000), with 
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significant differences by intervention condition (p=0.016) (Table 23). A similar pattern of response was observed when test 
termination time was used to represent cardiorespiratory fitness (Table 24).  
 
Table 22. Change in Absolute Cardiorespiratory Fitness (L/min) by treatment condition and Quartile of Baseline Klotho 
Treatment 
Baseline 
Klotho 
Quartile 
Absolute Cardiorespiratory Fitness 
(L/min) p-values 
Baseline 
Change 
from 
Baseline 
to  
6 Months 
Change 
from 
Baseline to 
12 Months 
Treatment 
Baseline 
Klotho 
Quartile 
Time Treatment X Time 
Baseline 
Klotho 
Quartile X 
Time 
Baseline 
Klotho 
Quartile X 
Treatment 
X Time 
DIET 
(N=51) 
Quartile 1 
(N=35) 2.2+0.5 -0.2+0.3 -0.1+0.3 
0.354 0.719 0.081 0.036 0.456 0.788 
 Quartile 2 
(N=36) 1.8+0.2 -0.1+0.2 -0.2+0.3 
 Quartile 3 
(N=38) 2.2+0.8 -0.1+0.2 -0.2+0.2 
 Quartile 4 
(N=38) 1.9+0.5 0.0+0.3 0.0+0.4 
DIET+150 
(N=45) 
Quartile 1 
(N=35) 2.1+0.6 0.0+0.2 0.0+0.2 
 Quartile 2 
(N=36) 2.2+0.6 0.0+0.3 0.0+0.2 
 Quartile 3 
(N=38) 2.0+0.5 0.0+0.2 0.0+0.2 
 Quartile 4 
(N=38) 2.0+0.4 0.0+0.3 0.0+0.2 
DIET+250 
(N=51) 
Quartile 1 
(N=35) 1.9+0.3 -0.1+0.1 0.0+0.2 
 Quartile 2 
(N=36) 2.2+0.6 0.1+0.2 0.0+0.2 
 Quartile 3 
(N=38) 2.0+0.3 -0.1+0.2 0.0+0.2 
 Quartile 4 
(N=38) 2.0+0.4 0.0+0.2 0.0+0.3 
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Table 23. Change in Relative Cardiorespiratory Fitness (ml/kg/min) by treatment condition and Quartile of Baseline Klotho 
Treatment 
Baseline 
Klotho 
Quartile 
Relative Cardiorespiratory Fitness 
(ml/kg/min) p-values 
Baseline 
Change 
from 
Baseline 
to  
6 Months 
Change 
from 
Baseline to 
12 Months 
Treatment 
Baseline 
Klotho 
Quartile 
Time Treatment X Time 
Baseline 
Klotho 
Quartile X 
Time 
Baseline 
Klotho 
Quartile X 
Treatment 
X Time 
DIET 
(N=51) 
Quartile 1 
(N=35) 23.6+5.0 1.5+2.9 3.0+4.1 
0.016 0.355 0.000 0.000 0.607 0.313 
 Quartile 2 
(N=36) 21.5+2.0 0.8+2.5 0.4+3.7 
 Quartile 3 
(N=38) 23.6+4.4 2.8+3.3 1.6+4.6 
 Quartile 4 
(N=38) 20.5+5.5 1.8+3.6 1.9+4.2 
DIET+150 
(N=45) 
Quartile 1 
(N=35) 23.5+5.2 3.4+3.7 4.1+4.1 
 Quartile 2 
(N=36) 23.9+4.8 4.7+5.5 6.3+3.4 
 Quartile 3 
(N=38) 23.3+5.4 2.6+3.7 3.3+4.3 
 Quartile 4 
(N=38) 22.2+3.9 5.6+4.6 5.9+3.6 
DIET+250 
(N=51) 
Quartile 1 
(N=35) 20.1+2.4 1.8+2.7 2.9+3.8 
 Quartile 2 
(N=36) 23.9+4.8 4.2+3.2 3.6+2.8 
 Quartile 3 
(N=38) 24.5+3.4 3.8+2.8 4.4+3.3 
 Quartile 4 
(N=38) 22.1+3.5 3.0+3.7 3.6+4.6 
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Table 24. Change in Cardiorespiratory Fitness (min) by treatment condition and Quartile of Baseline Klotho 
Treatment 
Baseline 
Klotho 
Quartile 
Cardiorespiratory Fitness (min) p-values 
Baseline 
Change 
from 
Baseline 
to  
6 Months 
Change 
from 
Baseline to 
12 Months 
Treatment 
Baseline 
Klotho 
Quartile 
Time Treatment X Time 
Baseline 
Klotho 
Quartile X 
Time 
Baseline 
Klotho 
Quartile X 
Treatment 
X Time 
DIET 
(N=51) 
Quartile 1 
(N=35) 7.8+2.8 2.3+0.0 2.0+0.2 
0.007 0.373 0.000 0.009 0.996 0.803 
 Quartile 2 
(N=37) 7.7+1.4 1.1+0.8 0.0+1.1 
 Quartile 3 
(N=38) 8.3+2.5 1.7+0.9 1.1+1.0 
 Quartile 4 
(N=38) 5.6+3.2 3.9+0.5 1.2+0.5 
DIET+150 
(N=45) 
Quartile 1 
(N=35) 8.5+3.5 3.0+1.4 3.0+1.0 
 Quartile 2 
(N=37) 8.4+3.5 3.1+0.8 3.9+1.5 
 Quartile 3 
(N=38) 8.1+4.1 2.2+0.4 2.3+0.5 
 Quartile 4 
(N=38) 8.0+2.4 3.4+0.8 2.8+1.1 
DIET+250 
(N=51) 
Quartile 1 
(N=35) 6.4+2.9 1.4+0.0 1.5+0.2 
 Quartile 2 
(N=37) 9.0+3.1 2.9+0.6 2.5+0.1 
 Quartile 3 
(N=38) 8.3+1.2 2.5+0.9 2.5+0.3 
 Quartile 4 
(N=38) 8.0+2.8 2.5+0.5 2.1+0.9 
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5.0 Discussion 
This study was conducted to examine changes in Klotho concentration in relation to a 12-
month behavioral weight loss intervention in adults with overweight or obesity. This study is 
important for the following reasons. First, few analyses have been conducted to examine the 
chronic changes in Klotho levels over time in adults with obesity, participating in a behavioral 
weight loss program. Moreover, studies that have investigated change in Klotho concentration 
have focused on response to an acute bout of exercise.11 The chronic changes that occur in 
Klotho concentration have not been examined. Moreover, whether weight loss has an effect on 
Klotho concentration is yet to be completely understood. Therefore, the current investigation 
examined how weight loss in conjunction with physical activity plays a role in Klotho 
concentration over a period of 12 months. 
5.1 Behavioral Weight Loss Intervention 
Data from the current study reveal a significant decrease in weight across the 12-month 
intervention. 29% (111 of 383) of the originally recruited participants lost > 10% of their 
baseline weight at 6 months and maintained this weight loss for the end of the 12-month 
intervention (Table 3). Similar weight loss patterns have been shown in the literature, with the 
STEP-UP135 randomized trial reporting ~20% of participants losing >10% of baseline weight and 
maintained this magnitude of weight loss throughout the duration of the trial.135 However, for the 
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current study there were no differences in the amount of weight loss by intervention condition 
(DIET vs. DIET+PA150 vs. DIET+PA250). 
Measures of body composition resulted in significant decreases in both volume of lean 
and fat mass across the 12-month intervention. Further, body composition was significantly 
different by weight loss response classification (Tables 5-7). This would be expected due to the 
stratification by weight loss of “responder” and “non-responder.” With loss of lean and fat mass 
being greater in the “responders” vs. “non-responders.” 
 Results show a significant increase in cardiorespiratory fitness across the 12-month 
intervention, with significant differences by intervention condition (Tables 8-10). The 
DIET+PA250 group had greater increases in relative cardiorespiratory fitness compared to the 
DIET+PA150 group, with both the DIET+PA150 and DIET+PA250 groups having greater 
increases in cardiorespiratory fitness compared to the DIET alone group. Results from the 
current study coincide with the literature on behavioral weight loss interventions that contain 
physical activity as a component, with the highest prescribed volume of activity having greater 
improvements in cardiorespiratory fitness.43,135,136 
5.2 Klotho Concentration 
This study aimed to examine change in Klotho concentration in participants who were 
overweight or obese undergoing a behavioral weight loss intervention, which also compared the 
effects of diet alone vs. diet combined with physical activity. For the current study, mean Klotho 
concentration was ~930 pg/mL. Amitani et al.,17 estimates normal weight individuals to have a 
Klotho concentration of 1391.6+145.0 pg/mL and individuals with obesity to have a Klotho 
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concentration of 847.1+111.3 pg/mL.17 The concentration of Klotho in the current study appears 
to be consistent with the level observed in other studies of adults with obesity.  
The premise of this study was to examine the potential link between obesity and klotho 
concentration. Obesity has been linked to many chronic conditions and promotion of advanced 
aging processes.127,129  Klotho has also been shown to be a marker of premature aging 
processes.12,13 Therefore, it was hypothesized when individuals who are overweight or obese 
undergo a weight loss intervention, Klotho concentration would increase and remain increased. 
However, the current study did not support this hypothesis, with Klotho concentration increasing 
modestly from baseline to 6 months, but not sustaining this rise in concentration from 6- to 12 
months.  Though not statistically significant, there appeared to be no change in Klotho 
concentration among individuals who lost weight with diet alone. However, results revealed a 
greater increase in Klotho concentration among individuals prescribed a higher volume of 
physical activity (Table 12 Figure 7), suggesting it may not be obesity that is linked to Klotho 
concentration, but rather physical activity that may have an important impact on Klotho 
concentration.  
5.2.1. Klotho Concentration, Obesity, and Weight Loss  
Klotho concentration, to the best our of knowledge, has not been reported in the literature 
for obese, but otherwise healthy adults prior to, during, and following a behavioral weight loss 
intervention. This 12-month intervention was effective in improving measures of weight and 
BMI status, body composition, and relative cardiorespiratory fitness (Tables 3-10). Participants 
in the current study were stratified by weight loss response (“responder” and “non-responder”), 
however Klotho concentration did not differ by classification or intervention condition (Table 
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13). While the intervention was successful in decreasing level of obesity, the effect on Klotho 
concentration was not as hypothesized. The decline in obesity among participants, lead to a 
modest and significant increase in Klotho concentration from baseline to 6 months, followed by 
a decline in Klotho concentration from 6- to 12 months (Table 12 and Figure 7).  Results suggest 
Klotho concentration may not be directly linked to obesity as originally hypothesized. Although 
weight loss did not appear to improve Klotho concentration among overweight and obese 
individuals, it also did not result in a Klotho concentration below baseline levels. Thus, weight 
loss does not appear to negatively influence Klotho concentration.  
Patterns of the body retracting back to baseline levels, similar to what was observe with 
Klotho in this study, has also been shown in patients who have undergone bariatric surgery. A 
randomized clinical trial from Courcoulas et al., observed significant weight loss among 
individuals who underwent bariatric surgery, which was maintained up to three years following 
the intervention.137 Moreover, 60% individuals who underwent Roux-en-Y Gastric Bypass 
(RYGB) surgery and 45% of individuals who underwent Lapriscopic adjustable gastric band 
(LAGB) surgery had complete or partial remission of type 2 diabetes at year one following 
surgery. However, three years following surgery only 29% of the RYGB and 40% of the LAGB 
participants remained in remission,137 potentially suggesting that the return to baseline levels in 
Klotho concentration in the current study may not be a unique phenomenon, but rather the 
body’s potential desire to return to baseline levels despite weight loss maintenance. This 
warrants further investigation.   
While not significant, an intriguing observation from this study revealed that a greater 
amount of physical activity prescribed was associated with a greater increase in Klotho 
concentration in the first 6 months of weight loss, as well as, a somewhat blunted decline in 
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Klotho concentration during months 6 to 12, with weight continually being maintained or lost 
(Table 12 Figure 7). This may indicate reducing sedentary time and increasing muscle activity 
through exercise may provide improvements in Klotho concentration, with a higher volume of 
physical activity being more beneficial than lower volumes to produce a change within the 
context of obesity and weight loss treatment.  
5.2.2. Klotho Concentration and Body Composition 
It is known that individuals with overweight and obesity tend to have greater functional 
impairment and decrements in musculoskeletal health. Klotho concentration has also been linked 
to declines in functional status in older adults.104,107 Thus, it would be hypothesized that higher 
levels of obesity would be associated with lower levels of Klotho concentration as measured by 
weight, BMI, lean mass, fat mass, and percent body fat. However, this relationship was not 
observed in this particular study.  These results could be due to a few reasons. The participants 
were an average of 45 years of age, which is younger than individuals examined in the literature 
that have shown relationships between Klotho and age-related health outcomes. Moreover, the 
participants in this current study did not have physical impairments which may have influenced 
the outcomes and their association with Klotho.  
Results from the current study reveal higher levels of Klotho concentration in individuals 
with a lower volume of lean mass (Table 17), potentially meaning volume of lean mass may not 
be completely linked to Klotho concentration. It is unknown if Klotho concentration may be 
affected by the quality of the skeletal muscle or lean body mass, rather than the total volume of 
lean body mass. This could be hypothesized because of obesity’s link to many metabolic 
alterations in muscle including changes in cellular location of fatty acid transporter proteins, 
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decreased mitochondrial enzyme activity, and defects in mitochondrial morphology.138-140 With 
these metabolic alterations, obesity is typically associated with an insulin resistant state, 
potentially where Klotho concentration may be impacted. The link between insulin/IGF-1 and 
Klotho concentration may be affected in obese individuals due to the increased volume of lean 
body mass and intramuscular adipose tissue that accumulates.  Within this pathway, obesity may 
decrease oxidative capacity and mitochondrial function, and therefore increasing oxidative stress 
on the body. Therefore, a potential hypothesis that may be drawn from these results is Klotho 
concentration is not influenced by the volume of lean body mass, but by the quality of the 
muscular tissue. This hypothesis warrants further investigation.   
This study used DXA to assess volume of lean mass. However, DXA does not provide a 
measure of muscle quality. Thus, measures to assess lean tissue and other components of body 
composition (e.g. MRI, CT, tissue biopsy, etc.) may be necessary to further investigate these 
relationships with Klotho in humans.  
Exercise has been shown throughout the literature to somewhat blunt lean body mass loss 
when individuals with obesity undergo weight loss.39,51 In an exploratory analysis, although not 
significant, results show individuals with a low baseline Klotho concentration do not preserve 
their lean body mass, even with high levels of physical activity being performed, compared to 
individuals with higher baseline levels of Klotho (Table 17). The prescribed mode of exercise in 
this study was primarily aerobic activity (e.g. walking). However, it is unknown is if other modes 
of physical activity (e.g. resistance exercise) would have resulted in different changes in lean 
mass loss and whether this would be associated with Klotho concentration. This may warrant 
further investigation.  
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5.2.3. Klotho Concentration as a Predictor to Key Variables 
Klotho concentration was analyzed as a predictor to changes in weight, body 
composition, and cardiorespiratory fitness. The literature has shown lower levels of Klotho 
concentration to be predictive of a decline in musculoskeletal health, cardiovascular disease, 
cognitive health, among other outcomes.104-107 However, this current study did not include 
measures of chronic disease and musculoskeletal health. Results did not consistently reveal 
baseline quartile of Klotho concentration to predict change in measures of weight, body 
composition, or cardiorespiratory fitness.  Thus, these variables included in weight loss 
treatment, may not be appropriate when assessing to Klotho concentration as a predictor of 
intervention response.  
5.3. Limitations and Future Directions 
While this study adds to the literature regarding Klotho and its association to body 
composition, weight loss, and physical activity, it is not without limitations that could impact the 
interpretation of the observed results. These limitations should also be considered as an 
opportunity for improving future research in this area of study. These include: 
1. This sample contained individuals who were overweight or obese but otherwise 
relatively healthy individuals. Participants were required to have the ability to walk 
on a treadmill at 3 miles per hour to measure cardiorespiratory fitness. Therefore, 
individuals in this study may not have functional impairments needed to observe 
associations with Klotho concentration that was originally hypothesized. This 
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outcome can potentially be due to the possibility that the level of obesity for 
participants in this study had not yet led to a decline in functional ability. Individuals 
with a broader range in functional ability should be examined to better understand the 
effect of weight and functional status on Klotho concentration.  
2. This study contains a subsample of the original 383 participants recruited for this 
standard behavioral weight loss intervention. The 152 participants who were included 
in this subsample were stratified into level of weight response classification to the 
weight loss intervention. Though weight loss of >10% is clinically meaningful, 
whether Klotho concentration significantly increases with weight loss at even higher 
levels may warrant further research.  
3. The current study involved moderate to high volumes of prescribed physical activity. 
As stated earlier, a higher volume of physical activity may produce significant 
changes in Klotho concentration, with diet alone producing no changes in Klotho 
concentration. Results from this study suggest future studies should asses the 
relationship between varying doses of prescribed physical activity and Klotho 
response.  
4. The prescribed physical activity in this study was primarily aerobic activity (e.g. 
walking). Moreover, volume of lean mass though non-significant, appeared to 
decrease further among individuals with lower baseline Klotho levels, even when a 
high volume of aerobic physical activity was prescribed. It is unclear how 
prescription of physical activity based on intensity or other modes of physical activity 
would have provided different results. Measuring other modes of physical activity, 
such as resistance training, may result in different effects on Klotho concentration and 
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lean mass. Further, it may be that only those who perform high intensities of physical 
activity, produce significant and sustainable changes in Klotho concentration, 
however this is unknown.  Although this analysis is outside of scope for this 
particular study, in the future studies could analyze how physical activity status may 
impact Klotho concentration within and outside of the context of a weight loss 
intervention.  
5. Individuals in this study were an average of 45 years of age, representing a younger 
population than typically reported in Klotho literature. The potential impact this 
intervention has on Klotho concentration in older individuals should be considered in 
future studies with obesity and measures of weight loss treatment.  
6. Lean mass has been used as a measure of musculoskeletal health (functional ability), 
and has been found to be associated with Klotho concentration, however there were 
no measures of this in the current study. As a measure of musculoskeletal health, 
functional ability and the effect it has on Klotho concentration, via measures such as 
the Senior Performance Physical Battery, Senior Fitness Test, 6-Minute Walk, and 
400 Meter Walk, may be important to include in future research studies.141,142 
7. Results from the current study show an inverse relationship between lean mass and 
Klotho concentration. These findings suggest that total volume of lean mass may not 
be a link to Klotho concentration as was hypothesized. What is not known is whether 
the quality of lean mass would provide additional understanding of this relationship. 
The measures of lean mass in this study did not account for an assessment of muscle 
quality. Therefore, future research studies should consider exploring both quality and 
volume of lean mass to better understand this relationship.  
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5.4. Summary 
In summary, this study quantified Klotho concentration in subjects who underwent a 
standard behavioral weight loss intervention for 12 months for the following Specific Aims. 
1. (Specific Aim 1) Examine Klotho concentration and its association to measures of 
body composition and fitness level: The current study revealed a significant an 
inverse relationship between lean body mass and Klotho concentration. However, no 
other measures were found to be statistically correlated with Klotho.  
2. (Specific Aim 2) Examine the change in Klotho concentration by intervention group 
across the 12-month weight loss intervention:  Results revealed significant changes in 
Klotho concentration across 12 months, however these changes did not differ by 
intervention group. Although non-significant, changes in Klotho concentration 
appeared greater among those individuals who were prescribed higher volumes of 
physical activity.  
3. (Specific Aim 3) Examine the change in Klotho concentration by both intervention 
group and weight loss classification (“responder” and “non-responder”) across the 12-
month intervention: The analysis revealed no significant difference by intervention 
condition or by response to achieve a weight loss of > 10% (“responders” vs. “non-
responders”).  
 
This study provides evidence within the context of a behavioral weight loss intervention, 
that Klotho concentration significantly but modestly increases when individuals undergo a 
weight loss intervention. However, this change may not be sustained overtime, despite sustained 
weight loss. Although the premise of this study to link obesity with Klotho concentration 
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because of a mutual relationship to advanced aging, the results from this study do not support 
there to be a relationship between these outcomes. However, results from this study showed that 
high volumes of prescribed physical activity were modestly and non-significantly associated 
with greater increases in Klotho concentrations. This may suggest stimulating muscle activity via 
physical activity may be an important contributor to increase Klotho concentration within the 
context of obesity that may require additional investigation. 
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Appendix A  
Human Klotho Elisa Kit Analysis 
Klotho was analyzed using ELISA kit steps developed by Immuno-Biological Laboratories, 
Takasaki, Japan.134 
Preparation steps were performed as follows: 
1.  Wash buffer concentration was diluted 40-fold with deionized water. The dilution 
was used for the assay as a wash buffer. (975 mL deionized water/25 mL wash buffer 
concentration) 
2. Labeled antibody concentration was diluted 30-fold with the solution for labeled 
antibody in a prepared collecting container. (11.6 mL solution for antibody/400 µL 
labeled antibody concentration) 
3. 0.5 mL of deionized water was added into the vial of Standard (recombinant human 
soluble α-Klotho) and was completely dissolved. Making the concentration of the 
standard to be 12,000 pg/mL. Seven test tubes for dilution of the standard were 
prepared, along with adding 300 µL of the EIA buffer into each tube. Next, 300 µL of 
the 12,000 pg/mL standard were placed into the tube 6,000 pg/mL (tube-1) and gently 
mixed. Afterword, 300 µL of the mixed liquid from tube-1 was placed into the tube 
3,000 pg/mL (tube-2) and gently mixed. Following, a dilution two-fold of the 
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standard solution was done in a series to set up 8 points of diluted standard between 
6,000 pg/mL and 93.75 pg/mL as follows: 
Tube-1  6,000  pg/mL 
Tube-2  3,000  pg/mL 
Tube-3  1,500  pg/mL 
Tube-4  750  pg/mL 
Tube-5  375  pg/mL 
Tube-6  187.5  pg/mL 
Tube-7  93.75  pg/mL 
Tube-8  46.875  pg/mL 
4. Test samples were diluted with EIA buffer 2-fold: 140 µL EIA buffer/140 µL test 
sample 
 
The measurement procedure was performed as follows:134 
1. Test sample blank wells were be determined, and 100 µL of EIA buffer was placed 
into the wells.  
2. 100 µL of prepared test samples and 100 µL of prepared standard were placed into 
appropriate wells.  
3. An incubation period of 60 minutes with the plate lid was performed at room 
temperature.  
4. The plate was washed with the prepared wash buffer four times, with all the liquid 
completely removed following the fourth wash. 
5. 100 µL of the prepared labeled antibody was added to the wells.  
81 
6. An incubation period of 30 minutes with the plate lid was performed at room 
temperature. 
7.   The plate was washed with the prepared wash buffer five times, with all the liquid 
completely removed following the fifth wash.  
8. 100 µL of Chormogen - TMB solution was added into the wells. 
9. An incubation period of 30 minutes in the dark was performed at room temperature.  
10. 100 µL of the Stop solution was added to the wells.  
11. Removal of dirt and drops of water on the bottom of the plate was done, as well as, 
confirmation that no bubbles are on the surface of the liquid. Then the optical density 
of the standard and the test samples was measured against a test sample blank, with 
the measurement wavelength at 450 nm. The minimum level of detectability of the 
assay was 6.15 pg/mL.  
 
Table 25. Breakdown of human soluble α-Klotho assay kit measurement procedures 
Reagents 
Test Sample Standard Test Sample Blank Reagent Blank 
Test Sample 
100 µL 
Diluted standard 
(Tube-1-7) 
100 µL 
EIA buffer 
(Tube-8) 
100 µL 
EIA buffer 
100 µL 
Incubation for 60 minutes at room temperature with plate lid 
4 times (wash buffer more than 350 µL) 
Labeled Antibody 100 µL 100 µL 100 µL - 
Incubation for 30 minutes at room temperature with plate lid 
5 times (wash buffer more than 350 µL) 
Chromogen 100 µL 100 µL 100 µL 100 µL 
Incubation for 30 minutes at room temperature (shielded) 
Stop solution 100 µL 100 µL 100 µL 100 µL 
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Calculation of the test result were performed as follows: 
1. Plot the concentration of the standard on the x-axis and its O.D. on the y-axis. Draw a 
standard curve by applying appropriate regression curve on each plot (i.e. linear 
curve)  
2. Read the concentration by applying the absorbance of the test samples on a standard 
curve.  
3. Calculate the concentration of the test samples by multiplying dilution ratio of the test 
samples on the value.   
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Appendix B  
Appendix B.1 Association Between Klotho Concentration and Measures of Weight, Body 
Composition, and Cardiorespiratory Fitness in “Responders” 
Table 26. Correlation between Baseline Klotho and change in weight, body composition, and 
cardiorespiratory fitness in “Responders” 
Variable  Baseline Klotho 
Body Weight (kg)                                                                  Change from Baseline to 6 Months* 
                                                                           Change from Baseline to 12 Months** 
r=0.175 (p=0.066) 
r=0.072 (p=0.450) 
 
Lean Mass (kg)                                                                        Change from Baseline to 6 Months* 
                                  Change from Baseline to 12 Months** 
r=0.190 (p=0.046) 
r=0.159 (p=0.095) 
 
Fat Mass (kg)                                                                         Change from Baseline to 6 Months* 
                                                                           Change from Baseline to 12 Months** 
r=0.098 (p=0.309) 
r=0.014 (p=0.887) 
 
Percent Body Fat                                                                   Change from Baseline to 6 Months* 
                                                                           Change from Baseline to 12 Months** 
r=0.012 (p=0.901) 
r= -0.046 (p=0.634) 
 
Absolute Cardiorespiratory Fitness (L/min)                         Change from Baseline to 6 Months* 
                                                                           Change from Baseline to 12 Months** 
r=0.215 (p=0.023) 
r=0.119 (p=0.214) 
 
Relative Cardiorespiratory Fitness (ml/kg/min)                    Change from Baseline to 6 Months* 
                                                                           Change from Baseline to 12 Months** 
r=0.153 (p=0.110) 
r=0.033 (p=0.731) 
 
Cardiorespiratory Fitness (minutes)                                      Change from Baseline to 6 Months* 
                                                                           Change from Baseline to 12 Months** 
r=0.027 (p=0.777) 
r= -0.007 (p=0.943) 
*Indicates change computed as Month 6 – Baseline 
**Indicates change computed as Month 12 – Baseline 
N=111 
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Table 27. Correlation between change in Klotho at 6 months and change in weight, body composition, and 
cardiorespiratory fitness at 6 months in “Responders” 
Variable  Baseline Klotho 
Body Weight (kg)                                                                  Change from Baseline to 6 Months* r= -0.052 (p=0.585) 
 
Lean Mass (kg)                                                                      Change from Baseline to 6 Months* r= 0.053 (p=0.581) 
 
Fat Mass (kg)                                                                         Change from Baseline to 6 Months* r= -0.052 (p=0.590) 
 
Percent Body Fat                                                                   Change from Baseline to 6 Months* r= 0.030 (p=0.754) 
 
Absolute Cardiorespiratory Fitness (L/min)                         Change from Baseline to 6 Months* r= -0.089 (p=0.352) 
 
Relative Cardiorespiratory Fitness (ml/kg/min)                    Change from Baseline to 6 Months* r= -0.112 (p=0.244) 
 
Cardiorespiratory Fitness (minutes)                                      Change from Baseline to 6 Months* r= -0.066 (p=0.493) 
 
*Indicates change computed as Month 6 – Baseline 
N=111 
 
Table 28. Correlation between change in Klotho at 12 months and change in weight, body composition, and 
cardiorespiratory fitness at 12 months in “Responders” 
Variable  Baseline Klotho 
Body Weight (kg)                                                              Change from Baseline to 12 Months** r= 0.075 (p=0.436) 
 
Lean Mass (kg)                                                                  Change from Baseline to 12 Months** r= 0.044 (p=0.648) 
 
Fat Mass (kg)                                                                     Change from Baseline to 12 Months** r= 0.070 (p=0.468) 
 
Percent Body Fat                                                               Change from Baseline to 12 Months** r= 0.012 (p=0.901) 
 
Absolute Cardiorespiratory Fitness (L/min)                     Change from Baseline to 12 Months** r=0.038 (p=0.691) 
 
Relative Cardiorespiratory Fitness (ml/kg/min)                Change from Baseline to 12 Months** r=0.057 (p=0.553) 
 
Cardiorespiratory Fitness (minutes)                                  Change from Baseline to 12 Months** r= 0.012 (p=0.902) 
 
**Indicates change computed as Month 12 – Baseline 
N=111 
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Appendix B.2 Baseline Quartile Klotho Concentration to Predict Change in Measures of Weight, Body Composition, and 
Cardiorespiratory Fitness in “Responders” 
Table 29. Change in Weight (kg) by treatment condition and Quartile of Baseline Klotho in “Responders” 
Treatment 
Baseline 
Klotho 
Quartile 
Weight (kg) p-values 
Baseline 6 Months 12 Months Treatment 
Baseline 
Klotho 
Quartile 
Time Treatment X Time 
Baseline 
Klotho 
Quartile X 
Time 
Baseline 
Klotho 
Quartile X 
Treatment 
X Time 
DIET 
(N=37) 
Quartile 1 
(N=27) 94.3+14.0 80.0+10.8 77.1+10.0 
0.988           0.448 0.000 0.340 0.624 0.861 
 Quartile 2 
(N=28) 83.4+9.4 69.8+7.8 67.0+7.4 
 Quartile 3 
(N=27) 91.5+18.5 77.0+14.9 73.9+15.1 
 Quartile 4 
(N=29) 91.6+11.0 80.4+8.6 76.5+12.4 
DIET+150 
(N=35) 
Quartile 1 
(N=27) 92.6+12.9 76.4+9.6 74.4+11.7 
 Quartile 2 
(N=28) 93.5+10.5 76.7+8.8 75.1+10.4 
 Quartile 3 
(N=27) 92.7+13.4 79.1+12.6 75.9+12.9 
 Quartile 4 
(N=29) 88.7+8.1 72.6+4.9 70.0+6.1 
DIET+250 
(N=39) 
Quartile 1 
(N=27) 98.5+18.7 82.9+15.6 78.7+17.8 
 Quartile 2 
(N=28) 94.6+13.7 80.0+13.0 78.3+12.8 
 Quartile 3 
(N=27) 81.2+10.0 67.0+9.3 66.8+8.4 
 Quartile 4 
(N=29) 88.1+15.0 75.5+13.4 72.7+13.0 
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Table 30. Change in Body Mass Index (kg/m2) by treatment condition and Quartile of Baseline Klotho in “Responders” 
Treatment 
Baseline 
Klotho 
Quartile 
Body Mass Index (kg/m2) p-values 
Baseline 6 Months 12 Months Treatment 
Baseline 
Klotho 
Quartile 
Time Treatment X Time 
Baseline 
Klotho 
Quartile X 
Time 
Baseline 
Klotho 
Quartile X 
Treatment 
X Time 
DIET 
(N=37) 
Quartile 1 
(N=27) 32.8+3.6 27.9+3.6 26.9+3.3 
0.917 0.337 0.000 0.218 0.564 0.731 
 Quartile 2 
(N=28) 31.2+3.5 26.1+3.0 25.1+3.0 
 Quartile 3 
(N=27) 31.6+2.4 26.7+2.1 25.5+2.0 
 Quartile 4 
(N=29) 32.0+2.9 28.1+2.6 26.6+2.0 
DIET+150 
(N=35) 
Quartile 1 
(N=27) 32.2+2.9 26.7+2.6 26.0+2.8 
 Quartile 2 
(N=28) 33.4+3.8 27.4+3.1 26.8+3.3 
 Quartile 3 
(N=27) 33.0+4.9 28.1+4.4 27.0+4.4 
 Quartile 4 
(N=29) 32.1+2.4 26.4+2.3 25.5+2.9 
DIET+250 
(N=39) 
Quartile 1 
(N=27) 35.5+4.6 30.0+4.1 28.4+5.0 
 Quartile 2 
(N=28) 32.5+3.9 27.5+3.9 26.9+3.9 
 Quartile 3 
(N=27) 29.6+2.8 24.4+2.6 24.3+2.4 
 Quartile 4 
(N=29) 31.4+4.3 27.0+4.0 25.9+3.5 
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Table 31. Change in Lean Mass (kg) by treatment condition and Quartile of Baseline Klotho in “Responders” 
Treatment 
Baseline 
Klotho 
Quartile 
Lean Mass (kg) p-values 
Baseline 6 Months 12 Months Treatment 
Baseline 
Klotho 
Quartile 
Time Treatment X Time 
Baseline 
Klotho 
Quartile 
X Time 
Baseline 
Klotho 
Quartile X 
Treatment 
X Time 
DIET 
(N=37) 
Quartile 1 
(N=27) 51.5+9.9 48.8+8.9 48.8+9.6 
0.688 0.505 0.000 0.517 0.260 0.354 
 Quartile 2 
(N=28) 43.0+4.4 40.6+4.1 40.6+4.2 
 Quartile 3 
(N=27) 50.0+12.9 47.1+11.2 47.2+10.7 
 Quartile 4 
(N=29) 46.0+9.7 44.3+9.1 44.1+10.3 
DIET+150 
(N=35) 
Quartile 1 
(N=27) 52.4+9.8 49.7+9.1 49.8+9.3 
 Quartile 2 
(N=28) 50.2+8.8 47.7+8.1 47.4+8.2 
 Quartile 3 
(N=27) 47.2+6.3 45.6+6.5 45.8+6.2 
 Quartile 4 
(N=29) 46.5+8.5 43.6+6.5 43.9+6.1 
DIET+250 
(N=39) 
Quartile 1 
(N=27) 47.2+6.2 45.1+5.6 44.9+6.0 
 Quartile 2 
(N=28) 49.9+7.4 47.0+6.6 46.9+6.5 
 Quartile 3 
(N=27) 45.1+4.5 43.8+4.8 44.3+4.8 
 Quartile 4 
(N=29) 46.5+8.9 45.5+9.4 45.1+9.3 
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Table 32. Change in Fat Mass (kg) by treatment condition and Quartile of Baseline Klotho in “Responders” 
Treatment 
Baseline 
Klotho 
Quartile 
Fat Mass (kg) p-values 
Baseline 6 Months 12 Months Treatment 
Baseline 
Klotho 
Quartile 
Time Treatment X Time 
Baseline 
Klotho 
Quartile X 
Time 
Baseline 
Klotho 
Quartile X 
Treatment 
X Time 
DIET 
(N=37) 
Quartile 1 
(N=27) 39.4+7.7 28.0+7.4 27.7+8.2 
0.749 0.572 0.000 0.227 0.726 0.928 
 Quartile 2 
(N=28) 37.3+5.0 26.5+4.0 28.0+8.5 
 Quartile 3 
(N=27) 38.6+6.6 26.9+4.2 26.2+8.1 
 Quartile 4 
(N=29) 42.0+3.2 33.2+3.6 28.2+6.9 
DIET+150 
(N=35) 
Quartile 1 
(N=27) 36.8+5.6 23.6+5.8 25.2+7.1 
 Quartile 2 
(N=28) 39.8+6.1 26.0+6.9 23.7+3.5 
 Quartile 3 
(N=27) 42.2+10.9 30.5+10.5 24.0+6.1 
 Quartile 4 
(N=29) 39.1+4.9 26.3+6.5 29.3+4.3 
DIET+250 
(N=39) 
Quartile 1 
(N=27) 47.6+14.5 34.8+11.7 21.6+5.2 
 Quartile 2 
(N=28) 41.2+10.7 30.1+10.7 24.8+7.6 
 Quartile 3 
(N=27) 33.1+7.0 20.5+5.8 27.4+10.8 
 Quartile 4 
(N=29) 38.4+8.1 27.3+7.6 23.7+6.7 
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Table 33.  Change in Percent Fat Mass (%) by treatment condition and Quartile of Baseline Klotho in “Responders” 
Treatment 
Baseline 
Klotho 
Quartile 
Percent Fat Mass (%) p-values 
Baseline 6 Months 12 Months Treatment 
Baseline 
Klotho 
Quartile 
Time Treatment X Time 
Baseline 
Klotho 
Quartile X 
Time 
Baseline 
Klotho 
Quartile X 
Treatment 
X Time 
DIET 
(N=37) 
Quartile 1 
(N=27) 42.0+5.5 35.2+7.4 32.9+8.1 
0.462 0.412 0.000 0.147 0.699 0.517 
 Quartile 2 
(N=28) 45.0+1.6 38.0+1.9 35.5+2.4 
 Quartile 3 
(N=27) 42.7+4.2 35.4+3.9 32.5+5.2 
 Quartile 4 
(N=29) 46.6+4.8 41.8+5.7 38.8+5.0 
DIET+150 
(N=35) 
Quartile 1 
(N=27) 40.2+4.8 31.1+7.1 29.2+5.7 
 Quartile 2 
(N=28) 43.0+6.0 34.0+8.4 32.8+8.5 
 Quartile 3 
(N=27) 45.3+7.0 38.0+8.5 35.2+9.3 
 Quartile 4 
(N=29) 44.6+6.0 36.3+8.3 33.7+8.2 
DIET+250 
(N=39) 
Quartile 1 
(N=27) 48.0+6.8 41.3+7.1 38.1+9.2 
 Quartile 2 
(N=28) 43.5+7.0 37.0+8.4 35.6+9.6 
 Quartile 3 
(N=27) 40.7+4.4 30.2+5.3 29.6+4.2 
 Quartile 4 
(N=29) 43.8+5.3 36.1+7.2 34.4+6.2 
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Table 34. Change in Absolute Cardiorespiratory Fitness (L/min) by treatment condition and Quartile of Baseline Klotho in “Responders” 
Treatment 
Baseline 
Klotho 
Quartile 
Absolute Cardiorespiratory Fitness 
(L/min) p-values 
Baseline 6 Months 12 Months Treatment 
Baseline 
Klotho 
Quartile 
Time Treatment X Time 
Baseline 
Klotho 
Quartile X 
Time 
Baseline 
Klotho 
Quartile X 
Treatment 
X Time 
DIET 
(N=37) 
Quartile 1 
(N=27) 2.3+0.5 2.1+0.4 2.1+0.4 
0.201 0.579 0.230 0.030 0.335 0.933 
 Quartile 2 
(N=27) 1.9+0.2 1.7+0.2 1.6+0.2 
 Quartile 3 
(N=27) 2.1+0.8 2.1+0.7 2.0+0.8 
 Quartile 4 
(N=29) 1.9+0.5 1.8+0.5 1.8+0.6 
DIET+150 
(N=34) 
Quartile 1 
(N=27) 2.4+0.5 2.3+0.6 2.4+0.6 
 Quartile 2 
(N=27) 2.2+0.6 2.3+0.7 2.2+0.5 
 Quartile 3 
(N=27) 2.0+0.4 2.0+0.4 2.0+0.5 
 Quartile 4 
(N=29) 2.0+0.4 2.0+0.4 2.0+0.3 
DIET+250 
(N=39) 
Quartile 1 
(N=27) 1.9+0.3 1.8+0.3 1.9+0.3 
 Quartile 2 
(N=27) 2.2+0.5 2.3+0.5 2.2+0.5 
 Quartile 3 
(N=27) 2.0+0.3 1.9+0.3 2.0+0.3 
 Quartile 4 
(N=29) 2.0+0.5 2.0+0.6 2.0+0.6 
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Table 35. Change in Relative Cardiorespiratory Fitness (ml/kg/min) by treatment condition and Quartile of Baseline Klotho in “Responders” 
Treatment 
Baseline 
Klotho 
Quartile 
Relative Cardiorespiratory Fitness 
(ml/kg/min) p-values 
Baseline 6 Months 12 Months Treatment 
Baseline 
Klotho 
Quartile 
Time Treatment X Time 
Baseline 
Klotho 
Quartile X 
Time 
Baseline 
Klotho 
Quartile X 
Treatment 
X Time 
DIET 
(N=37) 
Quartile 1 
(N=27) 24.0+4.9 25.8+4.0 27.7+3.8 
0.032 0.532 0.000 0.001 0.495 0.937 
 Quartile 2 
(N=27) 22.4+1.8 24.1+4.0 24.0+4.3 
 Quartile 3 
(N=27) 22.8+4.6 26.9+5.1 26.6+5.9 
 Quartile 4 
(N=29) 20.2+4.1 22.7+4.3 23.2+4.0 
DIET+150 
(N=34) 
Quartile 1 
(N=27) 25.8+5.0 30.7+6.2 32.1+6.1 
 Quartile 2 
(N=27) 23.9+4.8 30.1+9.1 30.3+6.8 
 Quartile 3 
(N=27) 21.7+4.9 26.2+6.1 27.3+6.5 
 Quartile 4 
(N=29) 22.2+3.9 27.8+5.9 28.1+4.9 
DIET+250 
(N=39) 
Quartile 1 
(N=27) 19.2+1.3 22.1+1.3 24.5+1.9 
 Quartile 2 
(N=27) 23.7+4.2 29.1+4.6 28.3+5.0 
 Quartile 3 
(N=27) 24.6+3.6 28.9+4.0 29.8+3.3 
 Quartile 4 
(N=29) 22.2+3.8 26.6+5.0 27.6+5.5 
 
 
 
92 
 
Table 36. Change in Cardiorespiratory Fitness (min) by treatment condition and Quartile of Baseline Klotho 
Treatment 
Baseline 
Klotho 
Quartile 
Cardiorespiratory Fitness (min) p-values 
Baseline 6 Months 12 Months Treatment 
Baseline 
Klotho 
Quartile 
Time Treatment X Time 
Baseline 
Klotho 
Quartile X 
Time 
Baseline 
Klotho 
Quartile X 
Treatment 
X Time 
DIET 
(N=37) 
Quartile 1 
(N=27) 8.2+278 10.7+2.5 10.4+2.5 
0.018 0.462 0.000 0.006 0.892 0.790 
 Quartile 2 
(N=27) 8.3+1.4 8.8+2.8 8.7+2.6 
 Quartile 3 
(N=27) 8.2+2.8 10.6+0.9 10.3+3.7 
 Quartile 4 
(N=29) 5.0+3.5 7.6+2.8 7.2+2.6 
DIET+150 
(N=34) 
Quartile 1 
(N=27) 9.5+3.1 13.7+4.7 13.8+3.4 
 Quartile 2 
(N=27) 8.4+3.5 11.6+4.3 12.3+5.0 
 Quartile 3 
(N=27) 7.5+4.2 11.2+4.8 10.9+3.9 
 Quartile 4 
(N=29) 8.0+2.4 11.4+3.2 10.8+3.5 
DIET+250 
(N=39) 
Quartile 1 
(N=27) 5.4+3.1 8.7+3.1 9.3+2.9 
 Quartile 2 
(N=27) 8.6+2.6 12.5+3.2 12.1+2.8 
 Quartile 3 
(N=27) 8.3+1.3 10.9+2.2 11.2+0.9 
 Quartile 4 
(N=29) 8.0+2.9 11.0+3.1 11.4+3.3 
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